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SCIENTIFIC OPINION 
Scientific Opinion on Flavouring Group Evaluation 9, Revision 6 
(FGE.09Rev6): Secondary alicyclic saturated and unsaturated alcohols, 
ketones and esters containing secondary alicyclic alcohols from  
chemical group 8 and 30, and an ester of a phenol derivative from  
chemical group 251 
EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
(CEF)2,3 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids of the European Food Safety 
Authority was requested to evaluate 22 flavouring substances in the Flavouring Group Evaluation 9, Revision 6, 
using the Procedure in Commission Regulation (EC) No 1565/2000. None of the substances was considered to 
have genotoxic potential. The substances were evaluated through a stepwise approach (the Procedure) that 
integrates information on structure–activity relationships, intake from current uses, toxicological threshold of 
concern and available data on metabolism and toxicity. The present revision of FGE.09 includes the assessment 
of one additional flavouring substance, trans-3-methyl-2-(2-pentenyl)-2-cyclopenten-1-one [FL-no: 07.219]. The 
Panel concluded that the 22 substances [FL-nos: 02.070, 02.075, 02.135, 02.167, 06.136, 07.059, 07.109, 07.202, 
07.203, 07.219, 07.255, 09.154, 09.355, 09.520, 09.618, 09.619, 09.621, 09.843, 09.870, 09.929, 09.935 and 
09.949] do not give rise to safety concerns at their levels of dietary intake, estimated on the basis of the MSDI 
approach. However, based on mTAMDI calculations, for 11 flavouring substances [FL-nos: 07.059, 07.109, 
07.202, 07.203, 09.154, 09.520, 09.618, 09.619, 09.843, 09.935 and 09.949] more reliable exposure data are 
required for a re-evaluation. For two substances [FL-nos: 07.219 and 09.929] no use levels are available and 
these should be submitted. Besides the safety assessment of these flavouring substances, the specifications for 
the materials of commerce have been considered. Specifications, including complete purity criteria and identity 
for the materials of commerce, have been provided for all candidate substances. 
© European Food Safety Authority, 2015 
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SUMMARY 
Following a request from the European Commission, the EFSA Panel on Food Contact Materials, 
Enzymes, Flavourings and Processing Aids (CEF Panel) was asked to deliver a scientific opinion on 
the implications for human health of chemically defined flavouring substances used in or on foodstuffs 
in the Member States. In particular, the Panel was requested to evaluate 22 flavouring substances in 
the Flavouring Group Evaluation (FGE) 9, Revision 6 (FGE.09Rev6), using the Procedure referred to 
in Commission Regulation (EC) No 1565/2000 “(hereinafter ‘the Procedure’)”. These flavouring 
substances belong to chemical groups 8, 25 and 30 of Annex I of the Commission Regulation (EC) No 
1565/2000. 
The present revision of FGE.09, FGE.09Rev6, includes the assessment of one additional candidate 
substance, trans-3-methyl-2-(2-pentenyl)-2-cyclopenten-1-one [FL-no: 07.219], which was not 
included in FGE.09Rev5. This substance is an α,β-unsaturated carbonyl, for which concern for 
genotoxicity was ruled out in FGE.212Rev3. 
FGE.09Rev6 deals with 22 candidate substances: secondary alicyclic saturated and unsaturated 
alcohols, ketones, one hemiketal ester and esters containing secondary alicyclic alcohols. 
Two candidate substances [FL-nos: 07.203 and 07.255] possess one chiral centre and 15 substances 
[FL-nos: 02.075, 02.167, 06.136, 07.059, 09.154, 09.355, 09.520, 09.618, 09.619, 09.621, 09.843, 
09.870, 09.929, 09.935 and 09.949] possess two or more chiral centres. 
Fourteen candidate substances belong to structural class I, seven substances belong to structural class 
II and one to structural class III according to the decision tree approach presented by Cramer et al. 
(1978). 
Fifteen flavouring substances in the present group have been reported to occur naturally in a wide 
range of food items. 
In its evaluation, the Panel as a default used the “Maximised Survey-derived Daily Intake” (MSDI) 
approach to estimate the per capita intakes of the flavouring substances in Europe. However, when the 
Panel examined the information provided by the European Flavour Industry on the use levels in 
various foods, it appeared obvious that the MSDI approach in a number of cases would grossly 
underestimate the intake by regular consumers of products flavoured at the use level reported by the 
Flavour Industry, especially in those cases where the annual production values were reported to be 
small. In consequence, the Panel had reservations about the data on use and use levels provided and 
the intake estimates obtained by the MSDI approach. 
In the absence of more precise information that would enable the Panel to make a more realistic 
estimate of the intakes of the flavouring substances, the Panel has decided also to perform an estimate 
of the daily intakes per person using a “modified Theoretical Added Maximum Daily Intake” 
(mTAMDI) approach based on the normal use levels reported by the Flavour Industry. In those cases 
where the mTAMDI approach indicated that the intake of a flavouring substance might exceed its 
corresponding threshold of concern, the Panel decided not to carry out a formal safety assessment 
using the Procedure. In these cases the Panel requires more precise data on use and use levels. 
According to the default MSDI approach, intakes in Europe of the 14 flavouring substances belonging 
to structural class I range from 0.0012 to 830 µg per capita per day, intakes of the seven substances 
from structural class II range from 0.0085 to 530 µg per capita per day and intake of the substance 
from structural class III is 1.2 µg per capita per day. These intakes are all below the threshold of 
concern values for structural classes I, II and III of 1 800, 540 and 90 µg per person per day, 
respectively. For one substance [FL-no: 09.520] from structural class II the MSDI is 770 µg per capita 
per day, which is above the threshold of concern of 540 µg per person per day. For this substance a No 
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Observed Adverse Effect Level (NOAEL) is available, providing a sufficient margin of safety based 
on the MSDI approach. 
The total combined intakes of candidate and supporting substances from structural classes I and II do 
not give rise to a safety concern. 
For five of the candidate substances [FL-nos: 07.109, 07.202, 07.219, 07.255 and 09.870] it has been 
concluded that a concern for genotoxicity, indicated by the presence of a structural alert, could be 
ruled out based on experimental data for supporting substances. Genotoxicity data are available for 
only a limited number of the remaining flavouring substances in the present group and the 
genotoxicity cannot be assessed adequately. However, the data available do not preclude evaluation of 
the substances using the Procedure. 
All candidate substances are expected to be metabolised to innocuous products at the estimated levels 
of use as flavouring substances. 
It was noted that where toxicity data were available they were consistent with the conclusions in the 
present FGE using the Procedure. 
It is considered that the 22 candidate substances would not give rise to safety concerns at the estimated 
levels of intake arising from their use as flavouring substances based on the default MSDI approach. 
In order to determine whether the conclusion for the 22 candidate substances, which have been 
evaluated using the Procedure, can be applied to the materials of commerce, it is necessary to consider 
the available specifications. Specifications, including complete purity criteria and information on 
identity for the materials of commerce, have been provided for all flavouring substances. 
Thus, for 22 flavouring substances evaluated using the Procedure, the Panel considered that the 
materials of commerce would not present a safety concern at their estimated levels of intake based on 
the MSDI approach [FL-nos: 02.070, 02.075, 02.135, 02.167, 06.136, 07.059, 07.109, 07.202, 07.203, 
07.219, 07.255, 09.154, 09.355, 09.520, 09.618, 09.619, 09.621, 09.843, 09.870, 09.929, 09.935 and 
09.949]. 
The estimated intakes of 13 candidate substances in structural class I, based on the mTAMDI 
approach, ranged from 420 to 63 000 µg per person per day. For six substances [FL-nos: 09.154, 
09.618, 09.619, 09.843, 09.935 and 09.949], the mTAMDI is above the threshold of concern of 
1 800 µg per person per day. For seven substances [FL-nos: 02.070, 02.075, 02.135, 02.167, 09.355, 
09.621 and 09.870], the mTAMDI is below the threshold. The mTAMDIs of five substances assigned 
to structural class II [FL-nos: 07.059, 07.109, 07.202, 07.203 and 09.520] range from 1 600 to 
8 700 µg per person per day, which are above the threshold of concern for structural class II 
substances of 540 µg per person per day. The mTAMDI estimates for one substance from structural 
class II [FL-no: 07.255] and for the one candidate substance in class III [FL-no: 06.136] are 320 and 
0.075 µg per person per day, respectively, which are below the thresholds of their structural classes 
(540 and 90 µg per person per day). For all substances with mTAMDI values below their structural 
class thresholds, the Panel noted that they have been evaluated using the A-side of the Procedure. 
For one flavouring substance [FL-no: 09.929] from structural class I and one flavouring substance 
[FL-no: 07.219] from structural class II, use levels are missing and an mTAMDI cannot be calculated 
for these two substances. 
In conclusion, for 11 candidate substances [FL-nos: 07.059, 07.109, 07.202, 07.203, 09.154, 09.520, 
09.618, 09.619, 09.843, 09.935 and 09.949], for which the mTAMDIs are above the thresholds for 
their structural class, and for another two substances [FL-nos: 07.219 and 09.929], for which use 
levels are missing, further information is required. This would include more reliable intake data and 
then, if required, additional toxicological data. 
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BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 
The use of flavouring is regulated under Regulation (EC) No 1334/20084 of the European Parliament 
and Council of 16 December 2008 on flavourings and certain food ingredients with flavouring 
properties for use in and on foods. On the basis of article 9(a) of this Regulation an evaluation and 
approval are required for flavouring substances. 
The Union List of flavourings and source materials was established by Commission Implementing 
Regulation (EC) No 872/2012.5 The list contains flavouring substances for which the scientific 
evaluation should be completed in accordance with Commission Regulation (EC) No 1565/2000.6 
On 25 November 2010, the EFSA Panel on Food Contact Materials, Enzymes, Flavourings and 
Processing Aids adopted an opinion on Flavouring Group Evaluation 212, Revision 1 (FGE.212Rev1): 
α,β-unsaturated alicyclic ketones and precursors from chemical subgroup 2.6 of FGE.19.7 
The Panel concluded that the argumentation of Industry to expand its conclusion for the six-carbon 
ring members of subgroup 2.6 also to the cyclopentenyl derivatives in this subgroup [FL-no: 07.033, 
07.094, 07.112 and 07.140] was considered too limited, given the lack of support from experimental 
data. Therefore, additional genotoxicity tests are still required for the representative substance [FL-no: 
07.112] already chosen by the Panel. Alternatively, a more thorough explanation (physico-chemical 
parameters; experimental underpinning) of the proposed similar reactivity of six- and five-membered 
ring substances should be provided by Industry. 
The requested data have been submitted by the applicant. 
In addition, the flavouring substance [FL-no: 07.219], trans-3-methyl-2-(2-pentenyl)-2-cyclopenten-1-
one, was put in FGE.212 (former FGE.19, subgroup 2.6b: α,β-unsaturated aldehydes and ketones and 
precursors) because of its structure relationship with this group. Although the substance as such is not 
mentioned in the data submitted by the applicant, the submitted data are likely to be relevant for [FL-
no: 07.219] as well. 
Therefore, this request covers as well the re-evaluation of trans-3-methyl-2-(2-pentenyl)-2-
cyclopenten-1-one [FL-no: 07.219]. 
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The European Commission requests the European Food Safety Authority (EFSA) to finalise its 
safety assessment of these flavouring substances in accordance with Commission Regulation (EC) 
No 1565/2000.6 
INTERPRETATION OF THE TERMS OF REFERENCE 
As additional genotoxicity data have been submitted to support evaluation of trans-3-methyl-2-(2-
pentenyl)-2-cyclopenten-1-one [FL-no: 07.219] with respect to genotoxic potential in FGE.212rev3. 
Subsequently, the European Commission requests EFSA to carry out a safety assessment in 
accordance with Commission Regulation (EC) No 1565/2000 for trans-3-methyl-2-(2-pentenyl)-2-
                                                     
4
 Regulation (EC) No 1334/2008 of the European Parliament and of the Council of 16 December 2008 on flavourings and 
certain food ingredients with flavouring properties for use in and on foods and amending Council Regulation (EEC) No 
1601/91, Regulations (EC) No 2232/96 and (EC) No 110/2008 and Directive 2000/13/EC. OJ L 354, 31.12.2008, p. 34–50. 
5
 EC (European Commission), 2012. Commission implementing Regulation (EU) No 872/2012 of 1 October 2012 adopting 
the list of flavouring substances provided for by Regulation (EC) No 2232/96 of the European Parliament and of the 
Council, introducing it in Annex I to Regulation (EC) No 1334/2008 of the European Parliament and of the Council and 
repealing Commission Regulation (EC) No 1565/2000 and Commission Decision 1999/217/EC. OJ L 267, 2.10.2012, p. 
1–161. 
6
 Commission Regulation No 1565/2000 of 18 July 2000 laying down the measures necessary for the adoption of an 
evaluation programme in application of Regulation (EC) No 2232/96. OJ L 180, 19.7.2000, p. 8–16. 
7
 EFSA Journal 2011;9(3):1923. 
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cyclopenten-1-one [FL-no: 07.219].The Panel concluded that [FL-no: 07.219] does not give rise to 
concern with respect to genotoxicity and can accordingly now be evaluated through the Procedure in 
FGE.09Rev6. 
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ASSESSMENT 
1. History of the evaluation of the substances in the present Flavouring Group Evaluation 
The Flavouring Group Evaluation (FGE) 09, FGE.09, dealt with 10 candidate substances, nine 
secondary alicyclic saturated and unsaturated alcohols, ketones and esters containing secondary 
alicyclic alcohols, and an ester of a phenol carboxylic acid and a secondary alicyclic alcohol. 
The first revision of FGE.09, FGE.09Rev1, included the assessment of five additional flavouring 
substances [FL-nos: 06.136, 09.154, 09.520, 09.929 and 09.935]. No new toxicity or metabolism data 
were provided for four of the five substances. For one substance [FL-no: 09.520] acute and short-term 
toxicity data and in vitro and in vivo genotoxicity data were provided. Additional data on five 
substances [FL-nos: 02.075, 02.167, 09.355, 09.619 and 09.621] were made available since FGE.09 
was published. 
The second revision of FGE.09, FGE.09Rev2, included the assessment of one additional substance, 
carvyl-3-methylbutyrate [FL-no: 09.870]. No toxicity and/or metabolism data were provided for this 
substance. Carvyl-3-methylbutyrate has initially been considered in FGE.212 with respect to 
genotoxicity, together with other α,β-unsaturated substances from subgroup 2.6 of FGE.19, where the 
Panel concluded that “d-Carvone [FL-no: 07.146] was found genotoxic in vitro. However, d-carvone 
was not carcinogenic in mice. Therefore, the Panel concluded that this substance together with the 
structurally related l-carvone as well as carveol and the carvyl derivatives [FL-nos: 02.062, 07.147, 
09.143, 09.215 and 09.870] could be evaluated through the Procedure”. 
The third revision of FGE.09, FGE.09Rev3, included the assessment of one additional substance, L-
menthyl (S)-3-hydroxybutyrate [FL-no: 09.949]. No toxicity and/or metabolism data were provided 
for this substance. 
The fourth revision of FGE.09, FGE.09Rev4, included the assessment of four additional substances 
[FL-nos: 07.059, 07.202, 07.255 and 09.843]. Two of these substances [FL-nos: 07.202 and 07.255] 
are α,β-unsaturated ketones originally allocated to FGE.212Rev1. The two substances were considered 
with respect to genotoxicity (EFSA CEF Panel, 2011) and the Panel concluded that the data available 
ruled out the concern for genotoxicity and accordingly the two substances could be evaluated through 
the Procedure. No toxicity or metabolism data were provided for the new substances. Since the 
publication of FGE.09Rev3, one substance (former candidate substance [FL-no: 07.207]) is no longer 
supported for use as a flavouring substance in Europe by the flavour industry and will therefore not be 
considered any further (EFFA, 2009). Information from the previous version of FGE.09 on this 
substance is to be kept in the main text only if relevant for the remaining candidate substances. 
The fifth revision of FGE.09, FGE.09Rev5, included the assessment of one additional substance, 
2,6,6-trimethylcyclohex-2-en-1,4-dione [FL-no: 07.109]. This substance is an α,β-unsaturated ketone 
originally allocated to FGE.213. The substance was considered with respect to genotoxicity in 
FGE.213Rev1 (EFSA CEF Panel, 2014) and the Panel concluded that the data available ruled out the 
concern for genotoxicity and accordingly the substance could be evaluated through the Procedure. No 
toxicity or metabolism data were provided for the substance.  
FGE Opinion 
adopted by 
EFSA 
Link No of 
candidate 
substances 
FGE.09 9 December 
2004 
http://www.efsa.eu.int/science/afc/afc_opinions/814_en.html 10 
FGE.09Rev1 1 April 2008 http://www.efsa.europa.eu/en/efsajournal/doc/927.pdf  15 
FGE.09Rev2 13 May 2009 http://www.efsa.europa.eu/en/efsajournal/pub/1454.htm 16 
FGE.09Rev3 28 September 
2011 
http://www.efsa.europa.eu/en/efsajournal/pub/2396.htm 17 
FGE.09Rev4 9 July 2012 http://www.efsa.europa.eu/en/efsajournal/pub/2836.htm 21 
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FGE Opinion 
adopted by 
EFSA 
Link No of 
candidate 
substances 
FGE.09Rev5 25 September 
2014 
http://www.efsa.europa.eu/en/efsajournal/doc/3865.pdf 21 
FGE.09Rev6 9 September 
2015 
http://www.efsa.europa.eu/en/efsajournal/doc/4243.pdf 22 
The present revision of FGE.09, FGE.09Rev6, includes the assessment of one additional substance 
[FL-no: 07.219]. This substance is an α,β-unsaturated ketone originally allocated to FGE.212. The 
substance has been considered with respect to genotoxicity in FGE.212Rev3 (EFSA CEF Panel, 2015) 
and the Panel concluded that the data available ruled out the concern for genotoxicity and accordingly 
the substance can be evaluated through the Procedure. No toxicity or metabolism data were provided 
for this candidate substance. A search in the open literature for the substance did not provide any 
further data on toxicity or metabolism. 
2. Presentation of the substances in Flavouring Group Evaluation 09, Revision 6 
2.1. Description 
The present FGE (FGE.09Rev6), using the Procedure referred to in Commission Regulation (EC) No 
1565/2000 (for a schematic form see Appendix A), deals with 10 secondary alicyclic saturated and 
unsaturated alcohols, ketones, one hemiketal ester and 11 esters containing secondary alicyclic 
alcohols. These 22 flavouring substances (candidate substances) belong to chemical groups 8, 25 and 
30 of Annex I of Regulation (EC) No 1565/2000. 
The candidate substances under consideration, with their chemical register names, FLAVIS (FL), 
Chemical Abstract Service (CAS), Council of Europe (CoE) and Flavor and Extract Manufacturers 
Association (FEMA) numbers, structure and specifications, are listed in Table 1. 
A summary of the outcome of the safety evaluation of the candidate substances is listed in Table 6. 
The hydrolysis products of the candidate substances and their evaluation status as flavouring 
substances are listed in Table 7. 
The candidate substances are structurally related to 27 flavouring substances (supporting substances) 
evaluated at the 51st, 59th and 63rd meetings of the Joint (Food and Agriculture Organization of the 
United Nations (FAO)/(World Health Organization (WHO) Expert Committee on Food Additives 
(JECFA, 2000a, 2003, 2005a, b) in the groups “Substances structurally related to menthol”, “Carvone 
and structurally related substances”, “Alicyclic ketones, secondary alcohols and related esters” and 
“Monocyclic and bicyclic secondary alcohols, ketones and related esters” (JECFA, 1999a, 2003, 
2006). In addition the racemate of menthyl-3-hydroxybutyrate has been evaluated by the JECFA at the 
69th meeting (JECFA, 2009) in the group of “Substances structurally related to menthol”. 
The names and structures for the 27 supporting substances are listed in Table 8, together with their 
evaluation status. 
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SUMMARY OF SPECIFICATION DATA 
 Specification Summary of the Substances in the FGE.09Rev6 Table 1: 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys. form 
Mol. formula 
Mol. weight 
Solubility (a) 
Solubility in 
ethanol (b) 
Boiling point, °C (c) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index  (d) 
Spec.gravity  (e) 
Specification 
comments 
02.070 Cyclohexanol 
 
 
2138 
108-93-0 
Solid 
C6H12O 
100.16 
Slightly 
soluble 
Freely 
soluble 
158 
25 
MS 
95 % 
1.462–1.468 
0.942–0.948 
 
 
02.075 (1R,2S,5S)-neo-
Dihydrocarveol 
 
 
2296 
18675-33-7 
Liquid 
C10H18O 
154.25 
Practically 
insoluble or 
insoluble 
Freely 
soluble 
107 (33 hPa) 
 
MS 
95 % 
1.476–1.482 
0.920–0.926 
 
 
02.135 Cyclopentanol 
 
 
10193 
96-41-3 
Liquid 
C5H10O 
83.13 
Slightly 
soluble 
Freely 
soluble 
140 
 
MS 
95 % 
1.449–1.455 
0.945–0.951 
 
 
02.167 (1R,2R,5S)-
Isodihydrocarveol 
 
 
 
18675-35-9 
Liquid 
C10H18O 
154.25 
Practically 
insoluble or 
insoluble 
Freely 
soluble 
90 (6.7 hPa) 
 
MS 
95 % 
1.475–1.481 
0.918–0.924 
 
 
OH
OH
OH
OH
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 Specification Summary of the Substances in the FGE.09Rev6 Table 1: 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys. form 
Mol. formula 
Mol. weight 
Solubility (a) 
Solubility in 
ethanol (b) 
Boiling point, °C (c) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index  (d) 
Spec.gravity  (e) 
Specification 
comments 
06.136 
1859 
6-Isopropyl-3,9-
dimethyl-1,4-
dioxyspiro[4.5]deca
n-2-one 
 
4285 
 
831213-72-
0 
Liquid 
C13H22O3 
226.32 
Slightly 
soluble 
Soluble 
259 
 
IR NMR MS 
98.9 % 
1.4606–1.4609 
1.017–1.021 
 
Mixture of 
isomers: (3S, 5R, 
6S,9R)-isomer: 
65.6 % and (3S, 
5S, 6S,9R)-isomer: 
27.4 %, mixture of 
other 
diastereomers: 
5.86 % (Flavour 
Industry, 2006b) 
07.059 p-Menthan-3-one 
 
2667 
2035 
10458-14-7 
Liquid 
C10H18O 
154.25 
Soluble 
Soluble 
207 
 
MS 
96 % 
1.448–1.453 
0.888–0.895 
 
Mixture of 
diastereomers, 
approximately 
25 % of each 
(EFFA, 2012) 
07.109 
1857 
2,6,6-
Trimethylcyclohex-
2-en-1,4-dione 
 
3421 
11200 
1125-21-9 
Solid 
C9H12O2 
152.2 
Slightly 
soluble 
Soluble 
222 
23–28 
IR NMR 
98 % 
n.a. 
n.a. 
 
 
07.202 2,6,6-
Trimethylcyclohex-
2-en-1-one 
 
 
 
20013-73-4 
Liquid 
C9H14O 
138.21 
Slightly 
soluble 
Freely 
soluble 
63 (16 hPa) 
 
MS 
95 % 
1.470–1.476 
0.924–0.930 
 
 
07.203 3,3,5-
Trimethylcyclohexa
n-1-one 
 
 
 
873-94-9 
Liquid 
C9H16O 
140.22 
Practically 
insoluble or 
insoluble 
Freely 
soluble 
189 
 
MS 
95 % 
1.442–1.448 
0.888–0.894 
 
Racemate (EFFA, 
2010a, b) 
O
O
O
O
O
O
O
O
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 Specification Summary of the Substances in the FGE.09Rev6 Table 1: 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys. form 
Mol. formula 
Mol. weight 
Solubility (a) 
Solubility in 
ethanol (b) 
Boiling point, °C (c) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index  (d) 
Spec.gravity  (e) 
Specification 
comments 
07.207 Cyclotetradecanone 
 
 
 
3603-99-4 
Solid 
C14H26O 
210.36 
Practically 
insoluble or 
insoluble 
Freely 
soluble 
159 (16 hPa) 
53 
NMR 
95 % 
n.a. 
n.a. 
 
No longer 
supported by the 
Flavour Industry 
(EFFA, 2009) 
07.219 
 
trans-3-Methyl-2-
(2-pentenyl)-2-
cyclopenten-1-one 
 
3196 
11786 
6261-18-3 
Liquid 
C11H16O 
164.25 
Soluble 
Soluble 
248 
 
MS 
98 % 
1.495–1.501 
0.942–0.948 
 
07.255 
1856 
l-Piperitone 
 
4200 
 
4573-50-6 
Liquid 
C10H16O 
152.24 
Slightly 
soluble 
Freely 
soluble 
246 
 
MS 
99 % 
1.482–1.488 
0.929–0.935 
 
09.154 
1852 
Menthyl valerate 
 
4156 
472 
89-47-4 
Liquid 
C15H28O2 
240.39 
Practically 
insoluble or 
insoluble 
Freely 
soluble 
261 
 
NMR 
95 % 
1.445–1.451 
0.903–0.909 
 
Register name to 
be changed to 
(1R,2S,5R)-5-
methyl-2-(1-
methylethyl)cycloh
exyl valerate 
(EFFA, 2010a) 
CH2
CH2
CH2
CH2
CH2
CH2C
H2
H2C
H2C
H2C
H2C
H2C
H2C
O
O
O
R
O
O
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 Specification Summary of the Substances in the FGE.09Rev6 Table 1: 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys. form 
Mol. formula 
Mol. weight 
Solubility (a) 
Solubility in 
ethanol (b) 
Boiling point, °C (c) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index  (d) 
Spec.gravity  (e) 
Specification 
comments 
09.355 neo-Dihydrocarvyl 
acetate 
 
 
10859 
56422-50-5 
Liquid 
C12H20O2 
196.29 
Practically 
insoluble or 
insoluble 
Freely 
soluble 
266 
 
MS 
95 % 
1.453–1.459 
0.925–0.931 
 
According to 
EFFA: Mixture of 
the two racemic 
forms (1S,2R,5R) 
and (1R,2S,5S), 
which is specified 
by the name 
(EFFA, 2005) 
09.520 
1898 
Methyl 3-oxo-2-
pentyl-1-
cyclopentylacetate 
 
3408 
10785 
24851-98-7 
Liquid 
C13H22O3 
226.32 
Slightly 
soluble 
Freely 
soluble 
111 (0.1 hPa) 
 
NMR MS 
98 % 
1.458–1.462 
0.997–1.006 
 
According to 
EFFA: Mixture of 
the four 
stereoisomeric 
forms (RR, RS, SR 
and SS) in 
relatively equal 
ratios 
(approximately 
25 % of each) 
(EFFA, 2010a) 
09.618 Menthyl formate 
 
 
10751 
2230-90-2 
Liquid 
C11H20O2 
184.28 
Practically 
insoluble or 
insoluble 
Freely 
soluble 
95 (13 hPa) 
9 
MS 
95 % 
1.446–1.452 
0.933–0.939 
 
According to 
EFFA: Mixture of 
the two racemic 
forms (1S,2R,5S) 
and (1R,2S,5R), 
which is specified 
by the name 
(EFFA, 2010b) 
O
O
O
O
O
OO
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 Specification Summary of the Substances in the FGE.09Rev6 Table 1: 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys. form 
Mol. formula 
Mol. weight 
Solubility (a) 
Solubility in 
ethanol (b) 
Boiling point, °C (c) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index  (d) 
Spec.gravity  (e) 
Specification 
comments 
09.619 
 
(1R,2S,5R)-Menthyl 
hexanoate 
 
 
 
6070-16-2 
Liquid 
C16H30O2 
254.14 
Practically 
insoluble or 
insoluble 
Freely 
soluble 
153 (20 hPa) 
 
MS 
95 % 
1.445–1.451 
0.898–0.906 
 
 
09.621 
 
(1R,2S,5R)-Menthyl 
salicylate 
 
 
 
89-46-3 
Liquid 
C17H24O3 
276.37 
Practically 
insoluble or 
insoluble 
Freely 
soluble 
175 (13 hPa) 
 
MS 
95 % 
1.509–1.515 
1.047–1.053 
 
 
09.843 
 
Menthol 1- and 2-
propylene glycol 
carbonate 
 
3806 
 
30304-82-6 
Liquid 
C14H26O4 
258.36 
Insoluble 
Soluble 
143 
 
IR MS 
98 % 
1.458–1.458 
1.013–1.014 
 
According to 
EFFA: [FL-no: 
09.843] is a 
mixture of 60 % 
menthol 1-
propylene glycol 
carbonate (which 
is a mixture of four 
stereoisomers, 
15 % of each) and 
40 % menthol 2-
propylene glycol 
carbonate (which 
is a mixture of four 
stereoisomers 
10 % of each) 
(EFFA, 2012) 
O
O
OHO
O
OH
O
O
O
+
O O
OH
O
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 Specification Summary of the Substances in the FGE.09Rev6 Table 1: 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys. form 
Mol. formula 
Mol. weight 
Solubility (a) 
Solubility in 
ethanol (b) 
Boiling point, °C (c) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index  (d) 
Spec.gravity  (e) 
Specification 
comments 
09.870 Carvyl-3-
methylbutyrate 
 
 
 
94386-39-7 
Liquid 
C15H24O2 
236.37 
Practically 
insoluble or 
insoluble 
Freely 
soluble 
343 
 
MS 
95 % 
1.462–1.468 
0.932–0.938 
 
According to 
EFFA: mixture of 
the four 
stereoisomeric 
forms (RR, RS, SR 
and SS) in 
relatively equal 
ratios 
(approximately 
25 % of each) 
(EFFA, 2010a) 
09.929 L-Monomenthyl 
glutarate 
 
4006 
 
220621-22-
7 
Liquid 
C15H26O4 
270 
Sparingly 
soluble 
Soluble 
390 (decomp) 
n.a. 
IR NMR 
95 % 
1.462–1.470 
1.026–1.036 
 
O
O
O
O
O
OH
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 Specification Summary of the Substances in the FGE.09Rev6 Table 1: 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys. form 
Mol. formula 
Mol. weight 
Solubility (a) 
Solubility in 
ethanol (b) 
Boiling point, °C (c) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index  (d) 
Spec.gravity  (e) 
Specification 
comments 
09.935 Dimenthyl glutarate  
 
406179-71-
3 
Solid 
C25H44O4 
408 
Insoluble 
Soluble 
 
48–50 
NMR MS 
98 % 
n.a. 
n.a. 
 
According to 
EFFA: Menthyl 
moiety mixture of 
the two racemic 
forms (1S,2R,5S) 
and (1R,2S,5R), 
which is specified 
by the name. Since 
there are two 
menthyl moieties, 
three combinations 
exist, 
approximately 
25 % (+/+), 25 % 
(–/–) and 50 % 
(+/–) (EFFA, 
2010a) 
 
09.949 
 
L-Menthyl (S)-3-
hydroxybutyrate 
 
4308 
 
115869-76-
6 
Liquid 
C14H26O3 
242.35 
Slightly 
soluble 
Soluble 
95–97 (0.7 hPa) 
 
IR MS 
98 % 
1.454–1.464 
0.969–0.979 
 
Stereoisomeric 
composition of (S)-
form: > 80 % ee 
and (R)-form 
< 20 % ee 
(ee = enantiomeric 
excess) 
ID, identity; IR, infrared spectroscopy; MS, mass spectrometry; n.a., not applicable; NMR, nuclear magnetic resonance. 
 (a): Solubility in water, if not otherwise stated. 
(b): Solubility in 95 % ethanol, if not otherwise stated. 
(c): At 1 013.25 hPa, if not otherwise stated. 
(d): At 20 °C, if not otherwise stated. 
(e): At 25 °C, if not otherwise stated. 
O
O
O
O
O
O OH
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2.2. Stereoisomers 
It is recognised that geometrical and optical isomers of substances may have different properties. Their 
flavour may be different, and they may have different chemical properties, resulting in possible 
variability in their absorption, distribution, metabolism, elimination and toxicity. Thus, information 
must be provided on the configuration of the flavouring substance, i.e. whether it is one of the 
geometrical/optical isomers or a defined mixture of stereoisomers. The available specifications of 
purity will be considered in order to determine whether the safety evaluation carried out for candidate 
substances for which stereoisomers may exist can be applied to the material of commerce. Flavouring 
substances with different configurations should have individual chemical names and codes (CAS 
number, FLAVIS number, etc.). 
Two candidate substances possess one chiral centre [FL-nos: 07.203 and 07.255] and 15 substances 
possess two or more chiral centres [FL-nos: 02.075, 02.167, 06.136, 07.059, 09.154, 09.355, 09.520, 
09.618, 09.619, 09.621, 09.843, 09.870, 09.929, 09.935 and 09.949] (Table 1). 
2.3. Natural occurrence in food 
Fifteen candidate substances [FL-nos: 02.070, 02.075, 02.135, 02.167, 07.059, 07.109, 07.202, 07.203, 
07.219, 07.255, 09.154, 09.355, 09.520, 09.618 and 09.619] have been reported to occur in fruits, 
spices, butter, chicken, wine, drinks, tea, juice and essential oils. Quantitative data on the natural 
occurrence of these substances in food have been reported for four substances (TNO, 2000, 2011, 
2014, 2015) (Table 2). 
 Candidate substances for which quantitative information on occurrence in food is Table 2: 
available 
FL-no Name Quantitative data reported 
02.070 Cyclohexanol Up to 0.1 mg/kg in fruits (passionfruit) and 
0.006 mg/kg in white wine 
02.135 Cyclopentanol 0.01–0.1 mg/kg in passiflora juice, 0.01–
0.1 mg/kg in Passiflora mollissima, 0.01–
0.02 mg/kg in oysters and 0.01 mg/kg in 
Chinese quince flesh 
07.109 2,6,6-Trimethylcyclohex-2-en-1,4-
dione 
Up to 8 mg/kg in honey for consumption 
and up to 9 mg/kg in tea 
07.202 2,6,6-Trimethylcyclohex-2-en-1-one 2 000 mg/kg in maize, 1 mg/kg in tea and 
up to 0.23 mg/kg in citrus fruits 
According to Nederlandse Organisatie voor Toegepast Natuurwetenschappelijk Onderzoek (TNO) the 
remaining seven candidate substances have not been reported to occur naturally in any food items 
(TNO, 2000, 2010, 2011) (Table 3). 
 Candidate substances not reported to occur naturally in food Table 3: 
FL-no Name 
06.136 6-Isopropyl-3,9-dimethyl-1,4-dioxyspiro[4.5]decan-2-one 
09.621 Menthyl salicylate 
09.843 Menthol 1-and 2-propylene glycol carbonate 
09.870 Carvyl-3-methylbutyrate 
09.929 L-Monomenthyl glutarate 
09.935 Dimenthyl glutarate 
09.949 L-Menthyl (S)-3-hydroxybutyrate 
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3. Specifications 
Purity criteria for the 22 candidate substances have been provided by the Flavour Industry (EFFA, 
2003a, 2010a, 2011; Flavour Industry, 2004, 2006a, b, 2007, 2010a). 
Judged against the requirements in Annex II of Commission Regulation (EC) No 1565/2000, the 
specifications are adequate for all substances (see Section 2.2 and Table 1). 
4. Intake data 
Annual production volumes of the flavouring substances as surveyed by the Flavour Industry can be 
used to calculate the “Maximised Survey-derived Daily Intake” (MSDI) by assuming that the 
production figure represents only 60 % of the use in food because of underreporting and that 10 % of 
the total European Union (EU) population are consumers (SCF, 1999). 
However, the Panel noted that because of year-to-year variability in production volumes, uncertainties 
in the underreporting correction factor and uncertainties in the percentage of consumers, the reliability 
of intake estimates on the basis of the MSDI approach is difficult to assess. 
The Panel also noted that, in contrast to the generally low per capita intake figures estimated on the 
basis of this MSDI approach, in some cases the regular consumption of products flavoured at use 
levels reported by the Flavour Industry in the submissions would result in much higher intakes. In 
such cases, the human exposure thresholds, below which exposures are not considered to present a 
safety concern, might be exceeded. 
Considering that the MSDI model may underestimate the intake of flavouring substances by certain 
groups of consumers, the Scientific Committee on Food (SCF) recommended also taking into account 
the results of other intake assessments (SCF, 1999). 
One of the alternatives is the “Theoretical Added Maximum Daily Intake” (TAMDI) approach, which 
is calculated on the basis of standard portions and upper use levels (SCF, 1995) for flavourable 
beverages and foods in general, with exceptional levels for particular foods. This method is regarded 
as a conservative estimate of the actual intake by most consumers because it is based on the 
assumption that the consumer regularly eats and drinks several food products containing the same 
flavouring substance at the upper use level. 
One option to modify the TAMDI approach is to base the calculation on normal rather than upper use 
levels of the flavouring substances. This modified approach is less conservative (e.g. it may 
underestimate the intake of consumers being loyal to products flavoured at the maximum use levels 
reported). However, it is considered as a suitable tool to screen and prioritise the flavouring substances 
according to the need for refined intake data (EFSA, 2004). 
4.1. Estimated daily per capita intake (MSDI Approach) 
The intake estimation is based on the MSDI approach, which involves the acquisition of data on the 
amounts used in food as flavourings (SCF, 1999). These data are derived from surveys on annual 
production volumes in Europe. These surveys were conducted in 1995 by the International 
Organization of the Flavor Industry (IOFI), in which flavour manufacturers reported the total amount 
of each flavouring substance incorporated into food sold in the EU during the previous year (IOFI, 
1995). The intake approach does not consider the possible natural occurrence in food. 
Average per capita intake (MSDI) is estimated on the assumption that the amount added to food is 
consumed by 10 % of the population8 (Eurostat, 1998). This is derived for candidate substances from 
                                                     
8
 EU figure: 375 million. This figure relates to EU population at the time for which production data are available, and is 
consistent (comparable) with evaluations conducted prior to the enlargement of the EU. No production data are available 
for the enlarged EU. 
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estimates of annual volume of production provided by the Flavour Industry and incorporates a 
correction factor of 0.6 to allow for incomplete reporting (60 %) in the Flavour Industry surveys (SCF, 
1999). 
In the present FGE.09Rev6, the total annual volume of production of the candidate substances from 
use as flavouring substances in Europe has been reported to be approximately 19 600 kg (EFFA, 
2003a, b, 2011; Flavour Industry, 2004, 2006a, b, 2007, 2010a, b). For 26 of the 27 supporting 
substances, for which production figures are available for Europe, the total annual volume of 
production is approximately 138 500 kg (JECFA, 1999a, 2003, 2006). 
On the basis of the annual volumes of production reported for the candidate substances, the MSDI 
values for each of these flavourings have been estimated (Table 6). 
Ninety-six per cent of the total annual volumes of production for the candidate substances is accounted 
for by four of these flavourings, p-menthan-3-one [FL-no: 07.059], methyl 3-oxo-2-pentyl-1-
cyclopentylacetate [FL-no: 09.520], menthol 1- and 2-propylene glycol carbonate [FL-no: 09.843] and 
L-monomenthyl glutarate [FL-no: 09.929]. The estimated daily intakes from use as flavouring 
substances are 530, 770, 830 and 110 µg per capita per day, respectively. The intakes for each of the 
remaining substances are 50 µg per capita per day or below (Table 6). 
4.2. Intake estimated on the basis of the modified TAMDI (mTAMDI) 
The method for calculation of the modified Theoretical Added Maximum Daily Intake (mTAMDI) 
values is based on the approach used by SCF up to 1995 (SCF, 1995). 
The assumption is that a person may consume a certain amount of flavourable foods and beverages per 
day. 
For the present evaluation of the candidate substances, information on food categories and normal and 
maximum use levels9,10,11 were submitted by the Flavour Industry (Burdock, 1995; EFFA, 2003a, 
2007; Flavour Industry, 2004, 2006a, b, 2007, 2010a, b). For 20 candidate substances, the use in 
flavoured food products divided into the food categories as outlined in Annex III of the Commission 
Regulation (EC) No 1565/2000, is shown in Table 4. For trans-3-methyl-2-(2-pentenyl)-2- 
cyclopenten-1-one [FL-no: 07.219] and L-monomenthyl glutarate [FL-no: 09.929] the use levels have 
not been reported in accordance with the Commission Regulation. 
For the present calculation of the mTAMDI, the reported normal use levels were used. In the case 
where different use levels were reported for different food categories the highest reported normal use 
level was used. 
 Use of 20 candidate substances for which data on use have been provided Table 4: 
Food 
category 
Description Flavourings used 
01.0 Dairy products, excluding products of category 2 All except one [FL-no: 
07.059] 
02.0 Fats and oils, and fat emulsions (type water-in-oil) All except four [FL-
nos: 07.059, 07.255, 
09.843 and 09.949] 
03.0 Edible ices, including sherbet and sorbet All 
                                                     
9
 “Normal use” is defined as the average of reported usages and “maximum use” is defined as the 95th percentile of reported 
usages (EFFA, 2002). 
10
 The normal and maximum use levels in different food categories [Reg. (EC) No 1565/ 2000] have been extrapolated from 
figures derived from 12 model flavouring substances (EFFA, 2004). 
11
 The use levels from food category 5 “Confectionery” have been inserted as default values for food category 14.2 
“Alcoholic beverages” for substances for which no data have been given for food category 14.2 (EFFA, 2007). 
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 Use of 20 candidate substances for which data on use have been provided Table 4: 
Food 
category 
Description Flavourings used 
04.1 Processed fruits All except four [FL-
nos: 06.136, 07.059, 
07.255 and 09.843] 
04.2 Processed vegetables (including mushrooms and fungi, roots and 
tubers, pulses and legumes), and nuts and seeds 
Only one [FL-no: 
09.935] 
05.0 Confectionery All 
06.0 Cereals and cereal products, including flours and starches from roots 
and tubers, pulses and legumes, excluding bakery 
All except four [FL-
nos: 07.059, 07.109, 
07.255 and 09.935] 
07.0 Bakery wares All 
08.0 Meat and meat products, including poultry and game All except five [FL-
nos: 06.136, 07.059, 
07.255, 09.843 and 
09.949] 
09.0 Fish and fish products, including molluscs, crustaceans and 
echinoderms  
All except five [FL-
nos: 06.136, 07.059, 
07.255, 09.843 and 
09.949] 
10.0 Eggs and egg products None 
11.0 Sweeteners, including honey None 
12.0 Salts, spices, soups, sauces, salads, protein products, etc. All except two [FL-
nos: 06.136 and 
07.059] 
13.0 Foodstuffs intended for particular nutritional uses All except five [FL-
nos: 07.059, 07.255, 
09.843, 09.935 and 
09.949] 
14.1 Non-alcoholic (“soft”) beverages, excluding dairy products All except one [FL-no: 
09.870] 
14.2 Alcoholic beverages, including alcohol-free and low-alcoholic 
counterparts 
All 
15.0 Ready-to-eat savouries All except two [FL-
nos: 06.136 and 
07.059]  
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat)—foods that 
could not be placed in categories 1–15 
All except two [FL-
nos: 07.059 and 
09.843] 
For the candidate substances for which the Flavour Industry has provided data on food categories, 
normal use levels are in the range of 0.0001–500 mg/kg food, and the maximum use levels are in the 
range of 0.0001–2000 mg/kg food (Burdock, 1995; EFFA, 2003a, 2007; Flavour Industry, 2004, 
2006a, b, 2007, 2010a, b). 
The mTAMDI values for 13 candidate substances from structural class I (see Section 7) for which 
exposure data have been submitted range from 420 to 63 000 µg per person per day. For the six 
candidate substances from structural class II, the mTAMDI values range from 320 to 8 700 µg per 
person per day. For the remaining substance from structural class III the mTAMDI is 0.075 µg per 
person per day. 
For detailed information on use levels and intake estimations based on the mTAMDI approach, see 
Section 7 and Appendix C. 
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5. Absorption, distribution, metabolism and elimination 
The 11 esters [FL-nos: 09.154, 09.355, 09.520, 09.618, 09.619, 09.621, 09.843, 09.870, 09.929, 
09.935 and 09.949] included in this FGE are expected to be hydrolysed to the corresponding 
carboxylic acids and alcohols, based on the data available for the supporting substances (White et al., 
1990; Emberger, 1994a, b). The resulting carboxylic acids are either metabolised through common 
physiological pathways, such as beta-oxidation and the citric acid cycle, or excreted in conjugation 
with glucuronide (Keefer et al., 1987; Vree et al., 1994) (see Table 7 and Appendix D). 
The one hemiketal ester [FL-no: 06.136] is expected to be hydrolysed to the corresponding cyclic 
ketone, p-menthan-3-one [FL-no: 07.059], and lactic acid [FL-no: 08.004]. 
One of the main pathways for the candidate alcohols and the ketones (after reduction) [FL-nos: 
02.070, 02.075, 02.135, 02.167, 07.059, 07.109, 07.202, 07.203, 07.219 and 07.255] is conjugation 
with glucuronic acid followed by excretion. Menthol, carveol and dihydrocarveol, the hydrolysis 
products of 11 substances [FL-nos: 06.136, 09.154, 09.355, 09.618, 09.619, 09.621, 09.843, 09.870, 
09.929, 09.935 and 09.949] are also metabolised via this pathway. Menthol, carveol and 
dihydrocarveol are not anticipated to be oxidised to the corresponding ketone (for detailed discussion, 
see Appendix D). 
Additional pathways involved in the metabolism of the candidate substances are reduction of ketone 
groups, oxidation of alkyl groups of alkyl substituted alicyclic ketones followed by conjugation with 
glucuronic acid and/or sulphates resulting in excretion (see Appendix D). Thus, it may be anticipated 
that these 22 substances will be metabolised to innocuous products. 
A more detailed description of the metabolism is given in Appendix D. 
6. Application of the procedure for the safety evaluation of flavouring substances 
The application of the Procedure is based on intakes estimated on the basis of the MSDI approach. 
Where the mTAMDI approach indicates that the intake of a flavouring substance might exceed its 
corresponding threshold of concern, a formal safety assessment, using the mTAMDI approach, is not 
carried out using the Procedure. In these cases, the Panel requires more precise data on use and use 
levels. For comparison of the intake estimations based on the MSDI approach and the mTAMDI 
approach, see Section 7. 
For the safety evaluation of the candidate substances the Procedure was applied. The stepwise 
evaluations are summarised in Tables 5 and 6. 
Step 1 
Fourteen of the candidate substances [FL-nos: 02.070, 02.075, 02.135, 02.167, 09.154, 09.355, 09.618, 
09.619, 09.621, 09.843, 09.870, 09.929, 09.935 and 09.949] are classified into structural class I, seven 
candidate substances [FL-nos: 07.059, 07.109, 07.202, 07.203, 07.219, 07.255 and 09.520] into 
structural class II and one substance [FL-no: 06.136] is classified into structural class III according to 
the decision tree approach presented by Cramer et al. (1978). 
Step 2 
Step 2 requires consideration of whether detoxification pathways are available to metabolise the 
substances, at the estimated levels of intake, to innocuous products. 
All the candidate substances [FL-nos: 02.070, 02.075, 02.135, 02.167, 06.136, 07.059, 07.109, 07.202, 
07.203, 07.219, 07.255, 09.154, 09.355, 09.520, 09.618, 09.619, 09.621, 09.843, 09.870, 09.929, 
09.935 and 09.949] are expected to be metabolised to innocuous products and, accordingly, they 
proceed via the A-side of the Procedure scheme (Section 5 and Appendix D). 
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Step A3 
For the 14 candidate substances [FL-nos: 02.070, 02.075, 02.135, 02.167, 09.154, 09.355, 09.618, 
09.619, 09.621, 09.843, 09.870, 09.929, 09.935 and 09.949] that have been assigned to structural class 
I, estimated European daily per capita intakes range from 0.0012 to 830 µg (Table 6). These intakes 
are below the threshold of concern of 1 800 µg per person per day for structural class I. 
For the seven candidate substances [FL-nos: 07.059, 07.109, 07.202, 07.203, 07.219, 07.255 and 
09.520] assigned to structural class II, European daily per capita intakes range from 0.0085 to 770 µg. 
For six of these [FL-nos: 07.059, 07.109, 07.202, 07.203, 07.219 and 07.255] the intakes are below the 
threshold of concern of 540 µg per person per day for structural class II. For one substance [FL-no: 
09.520] the daily per capita intake of 770 µg is above the threshold of concern for a substance 
assigned to structural class II. The substance therefore proceeds to step A4. 
One candidate substance [FL-no: 06.136] has been assigned to structural class III and its European 
daily per capita intake is 1.2 µg. This intake is below the threshold of concern of 90 µg per person per 
day for structural class III. 
Based on the results of the safety evaluation sequence, 21 candidate substances [FL-nos: 02.070, 
02.075, 02.135, 02.167, 06.136, 07.059, 07.109, 07.202, 07.203, 07.219, 07.255, 09.154, 09.355, 
09.618, 09.619, 09.621, 09.843, 09.870, 09.929, 09.935 and 09.949] proceeding via the A-side of the 
Procedure do not pose a safety concern when used at estimated levels of intake, based on the MSDI 
approach, as flavouring substances. 
Step A4 
Methyl 3-oxo-2-pentyl-1-cyclopentylacetate [FL-no: 09.520] and its metabolites are not endogenous; 
therefore, this substance proceeds to step A5. 
Step A5 
A 90-day study in rats has been performed for one substance [FL-no: 09.520] from which a No 
Observed Adverse Effect Level (NOAEL) of 100 mg/kg body weight (bw) per day could be derived. 
This NOAEL provides a margin of safety of 7 700 compared with the daily intake of 0.013 mg/kg bw 
per day for methyl 3-oxo-2-pentyl-1-cyclopentylacetate. Therefore, this substance [FL-no: 09.520] 
does not pose a safety concern when used at estimated levels of intake, based on the MSDI approach, 
as flavouring substance. 
7. Comparison of the intake estimations based on the MSDI and the mTAMDI approach 
The estimated intakes, based on the mTAMDI, range from 420 to 63 000 µg per person per day for 13 
candidate substances in structural class I. For seven of these substances [FL-nos: 02.070, 02.075, 
02.135, 02.167, 09.355, 09.621 and 09.870] the mTAMDI is below the threshold of concern of 
1 800 µg per person per day and for six substances [FL-nos: 09.154, 09.618, 09.619, 09.843, 09.935 
and 09.949] the mTAMDI is above the threshold. For L-monomenthyl glutarate [FL-no: 09.929] no 
mTAMDI could be calculated due to lack of information on use levels in the food categories as 
outlined in Annex III of Commission Regulation (EC) No 1565/2000. 
For six substances [FL-nos: 07.059, 07.109, 07.202, 07.203, 07.255 and 09.520] assigned to structural 
class II, the estimated intakes, based on the mTAMDI, range from 320 to 8 700 µg per person per day, 
which are all above the threshold of concern for structural class II substances of 540 µg per person per 
day, except for one substance [FL-no: 07.255]. For the seventh substance assigned to class II, trans-3-
methyl-2-(2-pentenyl)-2-cyclopenten-1-one [FL-no: 07.219], no mTAMDI could be calculated due to 
lack of information on use levels in the food categories as outlined in Annex III of Commission 
Regulation (EC) No 1565/2000. 
Flavouring Group Evaluation 09 Revision 6
 
EFSA Journal 2015;13(9):4243 23 
For one substance [FL-no: 06.136], assigned to structural class III, the estimated intake based on the 
mTAMDI is 0.075 µg per person per day, which is below the threshold of concern for a structural 
class II substance of 90 µg per person per day. 
Thus, for 10 candidate substances [FL-nos: 07.059, 07.202, 07.203, 09.154, 09.520, 09.618, 09.619, 
09.843, 09.935 and 09.949], further information is required. This would include more reliable intake 
data and then, if required, additional toxicological data. For trans-3-methyl-2-(2-pentenyl)-2-
cyclopenten-1-one [FL-no: 07.219] and L-monomenthyl glutarate [FL-no: 09.929] use levels are 
needed in accordance with the food categories as outlined in Annex III of Commission Regulation 
(EC) No 1565/2000. 
For comparison of the intake estimates based on the MSDI approach and the mTAMDI approach, see 
Table 5. 
 Estimated Intakes based on the MSDI Approach and the mTAMDI Approach Table 5: 
FL-no EU Register name MSDI (µg 
per capita 
per day) 
mTAMDI (µg 
per person 
per day) 
Structural 
class 
Threshold of 
concern (µg 
per person per 
day) 
02.070 Cyclohexanol 3.7 1 600 Class I 1 800 
02.075 (1R,2S,5S)-neo-Dihydrocarveol 2.4 1 600 Class I 1 800 
02.135 Cyclopentanol 0.012 1 600 Class I 1 800 
02.167 (1R,2R,5S)-Isodihydrocarveol 2.4 1 600 Class I 1 800 
09.154 Menthyl valerate 1 3 900 Class I 1 800 
09.355 neo-Dihydrocarvyl acetate 0.012 1 600 Class I 1 800 
09.618 Menthyl formate 0.73 3 900 Class I 1 800 
09.619 (1R,2S,5R)-Menthyl hexanoate 0.37 3 900 Class I 1 800 
09.621 (1R,2S,5R)-Menthyl salicylate 0.012 420 Class I 1 800 
09.843 Menthol 1-and 2-propylene 
glycol carbonate 
830 63 000 Class I 1 800 
09.870 Carvyl-3-methylbutyrate 0.0012 1 000 Class I 1 800 
09.929 L-Monomenthyl glutarate 110  Class I 1 800 
09.935 Dimenthyl glutarate 30 38 000 Class I 1 800 
09.949 L-Menthyl (S)-3-
hydroxybutyrate 
37 10 600 Class I 1 800 
07.059 p-Menthan-3-one 530 8 700 Class II 540 
07.109 2,6,6-Trimethylcyclohex-2-en-
1,4-dione 
50 1 900 Class II 540 
07.202 2,6,6-Trimethylcyclohex-2-en-
1-one 
0.12 1 600 Class II 540 
07.203 3,3,5-Trimethylcyclohexan-1-
one 
0.0085 1 600 Class II 540 
07.219 trans-3-Methyl-2-(2-pentenyl)-
2-cyclopenten-1-one 
4.7  Class II 540 
07.255 l-Piperitone 12 320 Class II 540 
09.520 Methyl 3-oxo-2-pentyl-1-
cyclopentylacetate 
770 3 900 Class II 540 
06.136 6-Isopropyl-3,9-dimethyl-1,4-
dioxyspiro[4.5]decan-2-one 
1.2 0.075 Class III 90 
8. Considerations of combined intakes from use as flavouring substances 
Because of structural similarities of candidate and supporting substances, it can be anticipated that 
many of the flavourings are metabolised through the same metabolic pathways and that the 
metabolites may affect the same target organs. Further, in case of combined exposure to structurally 
related flavourings, the pathways could be overloaded. Therefore, combined intake should be 
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considered. As flavourings not included in this FGE may also be metabolised through the same 
pathways, the combined intake estimates presented here are only preliminary. At present, the 
combined intake estimates are based only on MSDI exposure estimates, although it is recognised that 
this may lead to underestimation of exposure. After completion of all FGEs, this issue should be 
readdressed. 
The total estimated combined daily per capita intake of structurally related flavourings is estimated by 
summing the MSDI for individual substances. 
On the basis of the reported annual production volumes in Europe (EFFA, 2003a, b, 2011; Flavour 
Industry, 2004, 2006a, b, 2007, 2010a, b), the combined estimated daily per capita intake as 
flavourings of the 14 candidate substances assigned to structural class I is 1 000 µg, which does not 
exceed the threshold of concern of 1 800 µg per person per day. 
The candidate substances from structural class I are structurally related to 15 supporting substances for 
which European intake data are available (European intake data are available for only 15 of the 16 
supporting substances from structural class I). The total combined intake of the 14 candidate and 15 
supporting substances is approximately 17 000 µg per capita per day, which is above the threshold for 
structural class I substances of 1 800 µg per person per day. The major contribution (92 %) is provided 
by one supporting substance, menthol [FL-no: 02.015] (16 mg per capita per day), for which an 
Acceptable Daily Intake (ADI) of 0–4 mg/kg bw was allocated by the JECFA at its 51st meeting 
(JECFA, 2000a). The ADI is 15 times higher than the MSDI of 16 mg per capita per day. The total 
combined intake for the remaining substances from structural class I is approximately 1 400 µg per 
capita per day, which is below the threshold of 1 800 µg per person per day. 
On the basis of the reported annual production volumes in Europe, the combined estimated intake as 
flavourings of the candidate substances assigned to structural class II is 1 300 µg per capita per day, 
which exceeds the threshold of concern for a compound belonging to structural class II of 540 µg per 
person per day. A combined intake of 1 300 µg per capita per day corresponds to 22 µg/kg bw per day. 
A NOAEL of 100 mg/kg bw per day has been established for one candidate substance in this group, 
namely methyl 3-oxo-2-pentyl-1-cyclopentylacetate [FL-no: 09.520]. This NOAEL provides a margin 
of safety of more than 4 500 for the combined intake of 1 300 µg per capita per day. The Panel noted 
that this candidate substance [FL-no: 09.520] accounts for 60 % of this combined intake estimate. 
The total combined intake from the seven candidate and 15 supporting substances from structural class 
II is approximately 2 200 µg per capita per day, which exceeds the threshold for structural class II 
substances of 540 µg per person per day. Also in the case of the total combined intake for structural 
class II substances, the NOAEL of 100 mg/kg bw per day, for methyl 3-oxo-2-pentyl-1-
cyclopentylacetate, provides a margin of safety of 2 700 to the combined intake of 2 200 µg per capita 
per day, corresponding to 37 µg/kg bw per day. 
The daily per capita intake of the only candidate substance from structural class III, 6-isopropyl-3,9-
dimethyl-1,4-dioxyspiro[4.5]decan-2-one [FL-no: 06.136], is 1.2 µg, which does not exceed the 
threshold of 90 µg per person per day. There are no supporting substances from structural class III. 
9. Toxicity 
9.1. Acute toxicity 
Data are available for five candidate substances [FL-nos: 02.070, 02.135, 06.136, 09.520 and 09.355]. 
Oral median Lethal Dose (LD50) values from studies in the rat range from 625 mg/kg bw to 
> 5 000 mg/kg bw. 
Ten supporting substances [FL-nos: 02.015, 02.061, 02.062, 02.209, 07.111, 07.148, 07.176, 09.016, 
09.215 and 09.216] were tested for acute toxicity in the mouse, rat, rabbit, dog and guinea pig. The 
LD50 values ranged from 930 mg/kg bw to > 5 000 mg/kg bw. 
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The magnitudes of the LD50 values indicate that the oral acute toxicity is rather low for the candidate 
substances and supporting substances. 
The acute toxicity data are summarised in Table 14. 
9.2. Subacute, subchronic, chronic and carcinogenicity studies 
Only one conventional subchronic oral study has been conducted on one candidate substance [FL-no: 
09.520]. For cyclohexanol [FL-no: 02.070] data were available from a study designed to investigate 
only peripheral neuropathy in which rats were given intraperitoneal doses of 200 mg cyclohexanol 
once or twice daily for up to six weeks. No effects on the peripheral nervous system were observed but 
the experiment was terminated early because the animals were in poor condition, there was a 
decrement of weight gain and two animals died prematurely. No general gross or histopathological 
examinations were reported and no NOAEL was established. This study was not considered applicable 
to the evaluation of the oral toxicity of cyclohexanol (Perbellini et al., 1981). 
For methyl 3-oxo-2-pentyl-1-cyclopentylacetate [FL-no: 09.520] a study, following the current 
Organisation for Economic Co-operation and Development (OECD) guidelines, was performed in rats. 
Male and female Sprague–Dawley CD rats were given, in their diets, daily doses of 0 (basal diet), 10, 
50 or 100 mg/kg bw of methyl 3-oxo-2-pentyl-1-cyclopentylacetate over a 90-day period (10 males 
and 10 females per dose group). No treatment-related changes were observed in mortality, expanded 
clinical observations, ophthalmic examination, body weight gain, body weight change, food 
consumption, haematology, clinical chemistry, urinalysis, organ weights and macroscopic 
examination. There were no treatment-related histopathological changes in the tissues from rats of any 
of the treatment groups. The NOAEL was therefore considered to be 100 mg/kg bw per day (the 
highest dose tested) (Kelly and Bolte, 2000). 
Carcinogenicity studies are available for the two supporting substances, cyclohexanone and menthol 
[FL-nos: 07.148 and 02.015]. 
Cyclohexanone [FL-no: 07.148] was given to male and female rats in drinking water (doses of 3 300 
and 6 500 mg/kg) and male and female mice [doses of 6 500, 13 000 and 25 000 mg/kg (only female)] 
for two years. A reduction in weight gain (15–20 %) was observed in all groups at the highest doses. 
An increase in the incidence of lymphomas was observed at a lower dose level, but it was not dose 
related (Lijinsky and Kovatch, 1986). 
In two other studies, two doses of DL-menthol were given to rats in the diet (3 750 and 7 500 mg/kg) 
and mice (2 000 and 4 000 mg/kg) for 103 weeks. A small reduction in survival was seen in the treated 
female mice. An increase of incidence of mammary gland fibroadenomas or mammary 
adenocarcinomas was observed in female rats at the lower dose level, but this was not dose related. In 
male rats, dl-menthol was not considered toxic or carcinogenic. In mice, a small increase in the 
incidence of hepatocellular carcinomas was observed. However, this increase was within the normal 
range of tumour incidence in the historical control groups, and the authors concluded that dl-menthol 
was not carcinogenic in rats and mice in the performed studies (National Cancer Institute, 1979). 
For five supporting substances [FL-nos: 02.015, 07.095, 07.111, 07.176 and 07.148] there are further 
oral subchronic toxicity data. 
Repeated-dose toxicity data are summarised in Table 15. 
9.3. Developmental/reproductive toxicity studies 
There is a study available for one candidate substance [FL-no: 02.070], with a NOAEL of 
< 1 500 mg/kg bw per day. For one supporting substance [FL-no: 02.015] there are several studies. 
The developmental/reproductive toxicity study is summarised in Table 16. 
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9.4. Genotoxicity studies 
Owing to the presence of a structural alert for genotoxicity (“α,β-unsaturated carbonyl moiety”) for 
three candidate substances [FL-nos: 07.202, 07.255 and 09.870] in the current revision of FGE.09, the 
genotoxicity of these substances was further assessed in FGE.212 and FGE.212Rev1. In FGE.212 
(EFSA, 2009) the concern for carvyl-3-methylbutyrate [FL-no: 09.870] was alleviated and the Panel 
concluded that this substance could be evaluated through the Procedure. Since it was concluded in 
FGE.212Rev1 (EFSA CEF Panel, 2011) that, based on additional information, the concern for 
genotoxic potential for isophorone [FL-no: 07.126] has been alleviated, a genotoxic potential can also 
be ruled out for substances structurally related to isophorone (including [FL-nos: 07.202 and 07.255]). 
Therefore, these two substances [FL-nos: 07.202 and 07.255] can be evaluated using the Procedure. 
In FGE.212Rev3 (EFSA CEF Panel, 2015) it was concluded, that, based on additional information on 
the supporting substance 3-methyl-2-cyclopenten-1-one [FL-no: 07.112], the concern for genotoxicity 
for the candidate substance [FL-no: 07.219] could be ruled out. Therefore, this candidate substance 
can be evaluated using the Procedure. 
Owing to the presence of a structural alert for genotoxicity (“α,β-unsaturated ketone”) for the 
candidate substance 2,6,6-trimethylcyclohex-2-en-1,4-dione [FL-no: 07.109], the genotoxicity of this 
substance was assessed in FGE.213 and FGE.213Rev1. In FGE.213Rev1 the concern was alleviated 
and the Panel concluded that this substance could be evaluated through the Procedure (EFSA CEF 
Panel, 2014). 
Genotoxicity data are available for only three of the remaining candidate substances—cyclohexanol 
[FL-no: 02.070], cyclopentanol [FL-no: 02.135], methyl 3-oxo-2-pentyl-1-cyclopentylacetate [FL-no: 
09.520]—and for nine supporting substances and one structurally related substance. 
Cyclohexanol [FL-no: 02.070] was not genotoxic in two Ames tests (Barsky, 1976; Haworth et al., 
1983) and in an in vivo micronucleus assay (Gelbke, 1991), which are all considered valid studies. 
However, the results of the in vivo study are of limited relevance, because of the lack of evidence that 
the substance did reach the bone marrow. Inconclusive results were reported in an in vitro 
chromosomal aberration assay with human leucocytes (Collin, 1971) and negative results were 
reported in a dominant lethal mutations assay with Drosophila melanogaster (Goncharova, 1970); 
both studies were considered inadequate. 
Cyclopentanol [FL-no: 02.135] was studied in a valid Ames test (McMahon et al., 1979). No 
mutagenicity was found. 
A battery of in vitro and in vivo genotoxicity studies were conducted on methyl 3-oxo-2-pentyl-1-
cyclopentylacetate [FL-no: 09.520] including valid negative reverse mutation tests in E. coli (Wagner 
and Klug, 2000) and S. typhimurium (Thompson, 2000). 
In a mouse lymphoma test on methyl 3-oxo-2-pentyl-1-cyclopentylacetate [FL-no: 09.520], pre-dating 
Good Laboratory Practice (GLP), a more than twofold increase in the mutant frequency over the 
solvent-treated control values was found at the highest tested cytotoxic concentration of 300 µg/ml in 
the presence of metabolic activation, and at the two highest tested cytotoxic concentrations of 200 and 
300 µg/ml in the absence of metabolic activation. Only limited documentation is provided in the study 
report; together with the fact that several cultures were infected and a lack of a confirmatory test, it is 
impossible to assess the reliability of these results (Ross and Harris, 1979). 
No induction of forward mutations at the thymidine kinase (TK) locus in L5178Y mouse lymphoma 
cells were found in a study performed in compliance with the current OECD test guidelines, both in 
the absence and in the presence of metabolic activation, up to and including cytotoxic concentrations 
(Cifone, 2001). 
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Methyl 3-oxo-2-pentyl-1-cyclopentylacetate was tested in a bone marrow micronucleus test in mice 
following a single intraperitoneal administration of 0, 280, 560 or 1 120 mg/kg bw in corn oil. The 
study was performed in compliance with the current OECD test guidelines. The two highest doses 
chosen induced clear signs of toxicity; slight reductions (up to 12 %) in the ratio of polychromatic 
erythrocytes to total erythrocytes were found, indicating that the test material had reached the target 
cells. No increase in micronucleated cells was found in the groups treated with the test material. The 
positive control induced the expected increases (Gudi and Krsmanovic, 1998). 
In an Unscheduled DNA Synthesis (UDS) study, the ability of methyl 3-oxo-2-pentyl-1-
cyclopentylacetate to induce DNA repair was studied in isolated rat hepatocytes after administration in 
vivo. The study was performed in compliance with the current OECD Guideline 486 (OECD, 1997c). 
Methyl 3-oxo-2-pentyl-1-cyclopentylacetate was administered to male Sprague–Dawley CD rats by 
intraperitoneal injection in doses of 333.3 and 1 000 mg/kg bw (the latter dose was the maximum 
tolerated dose) followed by liver perfusion at 2 or 16 hours after dosing. No marked increase in the 
incidence of UDS was observed at either dose level or perfusion time. Statistically significant 
differences were revealed in the positive control groups when compared with the negative control 
group and the test article (Durward, 2001). 
Genotoxicity data are available for nine supporting substances [FL-nos: 02.015, 02.062, 07.045, 
07.148, 07.149, 07.176, 09.027, 09.215 and 09.230]. 
Cyclohexanone [FL-no: 07.148], structurally related to the alicyclic ketones and secondary alcohols in 
this FGE, was not mutagenic in an Ames test, which was considered to be valid (Haworth et al., 1983). 
Negative and positive results were reported in several other in vitro studies at gene and chromosomal 
level, as well as a negative result in a sex-linked recessive lethal mutations in D. melanogaster. 
However, these studies were considered inadequate. 
Menthol [FL-no: 02.015] gave negative results in an in vitro alkaline elution assay for detecting DNA 
single strand breaks in rat hepatocytes (Storer et al., 1996). With the same substance equivocal results 
in an in vivo host-mediated mutation assay were observed at high-dose levels (Food and Drug 
Research Laboratories, Inc., 1975) and negative results in several Ames tests, a TK+/– mouse 
lymphoma assay (Myhr and Caspary, 1991), sister chromatid exchange (SCE) tests in Chinese hamster 
ovary (CHO) cells (Ivett et al., 1989) and human lymphocytes (Murthy et al., 1991), and chromosomal 
aberration assays with human embryonic lung cells (Food and Drug Research Laboratories, Inc., 
1975), human lymphocytes (Murthy et al., 1991) and CHO cells (Ivett et al., 1989). Negative results 
were also reported in two in vivo micronucleus (Shelby et al., 1993) and chromosomal aberration 
assays (Food and Drug Research Laboratories, Inc., 1975). However, the results of these studies have 
a limited relevance, owing to the lack of bone marrow toxicity. In addition, an in vivo dominant lethal 
assay was available, from which negative results were also obtained. 
trans-Menthone [FL-no: 07.176] was genotoxic in an Ames test (Andersen and Jensen, 1984) and in a 
somatic mutation and recombination test (SMART) with D. melanogaster (Franzios et al., 1997). The 
observed effects were not very pronounced. Further, trans-menthone is easily converted to menthol, 
which is estimated to be, overall, negative in genotoxicity tests. 
Carveol and carvyl acetate [FL-nos: 02.062 and 09.215] were tested in an Ames test at various doses 
from 10 to 560 µg/plate in the S. typhimurium strains TA97, TA98, TA100, TA1535 and TA1537 with 
and without S9 mix in dimethyl sulphoxide. Positive and negative controls were used. No 
mutagenicity was observed (Mortelmans et al., 1986). 
Conclusion on genotoxicity 
For five of the candidate substances [FL-nos: 07.109, 07.202, 07.219, 07.255 and 09.870] it has been 
concluded that a concern for genotoxicity, indicated by the presence of a structural alert, could be 
ruled out based on experimental data for supporting substances. 
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Some genotoxicity data are available for only three of the remaining candidate substances, and for 
these three mainly negative results were obtained. For the supporting substances, mainly negative, but 
also some positive results were obtained. The positive results were obtained from poorly reported 
tests, or tests that are difficult to interpret with respect to their relevance for genotoxicity. 
Overall, the genotoxic potential of this group of flavouring substances cannot be fully assessed as it is 
now. However, the data available do not indicate a genotoxic potential and therefore do not preclude 
their evaluation via the Procedure. 
Data on genotoxicity are summarised in Tables 17 (in vitro) and 18 (in vivo). 
CONCLUSIONS 
The present revision of FGE.09, FGE.09Rev6, includes the assessment of one additional candidate 
substance, trans-3-methyl-2-(2-pentenyl)-2-cyclopenten-1-one [FL-no: 07.219], which was not 
included in FGE.09Rev5. 
FGE.09Rev6 deals with 22 candidate substances; secondary alicyclic saturated and unsaturated 
alcohols, ketones, one hemiketal ester and esters containing secondary alicyclic alcohols. These 
flavouring substances belong to chemical groups 8, 25 and 30 of Annex I of Regulation (EC) No 
1565/2000. 
Two candidate substances [FL-nos: 07.203 and 07.255] possess one chiral centre and 15 substances 
[FL-nos: 02.075, 02.167, 06.136, 07.059, 09.154, 09.355, 09.520, 09.618, 09.619, 09.621, 09.843, 
09.870, 09.929, 09.935 and 09.949] possess two or more chiral centres. 
Fourteen candidate substances belong to structural class I, seven substances belong to structural class 
II and one to structural class III according to the decision tree approach presented by Cramer et al. 
(1978). 
Fifteen of the flavouring substances in the present group have been reported to occur naturally in a 
wide range of food items. 
According to the default MSDI approach, intakes in Europe of the 14 flavouring substances belonging 
to structural class I rangefrom 0.0012 to 830 µg per capita per day, intakes of the seven substances 
from structural class II range from 0.0085 to 530 µg per capita per day and intake of the substance 
from structural class III  is 1.2 µg per capita per day, which are all below the threshold of concern 
values for structural classes I, II or III of 1 800, 540 or 90 µg per person per day, respectively. For one 
substance [FL-no: 09.520] from structural class II, the MSDI is 770 µg per capita per day, which is 
above the threshold of concern of 540 µg per person per day. For this substance a NOAEL is 
available, providing a sufficient margin of safety based on the MSDI approach. 
The total combined intakes of candidate and supporting substances from structural classes I and II do 
not give rise to a safety concern. 
For five candidate substances [FL-nos: 07.109, 07.202, 07.219, 07.255 and 09.870] it has been 
concluded that a concern for genotoxicity, indicated by the presence of a structural alert, could be 
ruled out based on experimental data for supporting substances. Genotoxicity data are available for 
only a limited number of the remaining flavouring substances in the present group and the 
genotoxicity cannot be assessed adequately. However, the data available do not preclude evaluation of 
the substances using the Procedure. 
All 22 candidate substances are expected to be metabolised to innocuous products at the estimated 
levels of use as flavouring substances. 
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It was noted that where toxicity data were available they were consistent with the conclusions in the 
present FGE using the Procedure. 
It is considered that the 22 candidate substances would not give rise to safety concerns at the estimated 
levels of intake arising from their use as flavouring substances based on the default MSDI approach. 
In order to determine whether the conclusion for the 22 candidate substances, which have been 
evaluated using the Procedure, can be applied to the materials of commerce, it is necessary to consider 
the available specifications. Specifications, including complete purity criteria and information on 
identity for the materials of commerce, have been provided for all flavouring substances. 
Thus, for 22 flavouring substances evaluated using the Procedure, the Panel considered that the 
materials of commerce would not present a safety concern at their estimated levels of intake based on 
the MSDI approach [FL-nos: 02.070, 02.075, 02.135, 02.167, 06.136, 07.059, 07.109, 07.202, 07.203, 
07.219, 07.255, 09.154, 09.355, 09.520, 09.618, 09.619, 09.621, 09.843, 09.870, 09.929, 09.935 and 
09.949]. 
The estimated intakes for 13 candidate substances in structural class I, based on the mTAMDI 
approach, ranged from 420 to 63 000 µg per person per day. For six substances [FL-nos: 09.154, 
09.618, 09.619, 09.843, 09.935 and 09.949], the mTAMDI is above the threshold of concern of 
1 800 µg per person per day. For seven substances [FL-nos: 02.070, 02.075, 02.135, 02.167, 09.355, 
09.621 and 09.870], the mTAMDI is below the threshold. The mTAMDIs of five substances assigned 
to structural class II range from 1 600 to 8 700 µg per person per day, which are above the threshold of 
concern for structural class II substances of 540 µg per person per day. The mTAMDI estimates for 
one substance from structural class II [FL-no: 07.255] and for the one candidate substance in class III 
[FL-no: 06.136] are 320 and 0.075 µg per person per day, respectively, which are below the thresholds 
of their structural classes (540 and 90 µg per person per day). For all substances with mTAMDI values 
below their structural class thresholds, the Panel noted that they have been evaluated via the A-side of 
the Procedure. 
For one flavouring substance [FL-no: 09.929] from structural class I and one flavouring substance 
[FL-no: 07.219] from structural class II, use levels are missing and an mTAMDI cannot be calculated 
for these two substances. 
In conclusion, for 11 candidate substances [FL-nos: 07.059, 07.109, 07.202, 07.203, 07.219 09.154, 
09.520, 09.618, 09.619, 09.843, 09.935 and 09.949], for which the mTAMDIs are above the 
thresholds for their structural class, and for another two substances [FL-nos: 07.219 and 09.929], for 
which use levels are missing, further information is required. This would include more reliable intake 
data and then, if required, additional toxicological data. 
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ABBREVIATIONS 
ADI Acceptable Daily Intake 
bw body weight 
CAS Chemical Abstract Service 
CEF EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
Chemical Abstract Service 
CHO Chinese hamster ovary (cells) 
CoE Council of Europe 
DNA Deoxyribonucleic acid 
EC European Commission 
EFFA European Flavour and Fragrance Association 
FAO Food and Agriculture Organization of the United Nations 
FEMA Flavor and Extract Manufacturers Association 
FGE Flavouring Group Evaluation 
GLP Good Laboratory Practice 
FLAVIS (FL) Flavour Information System (database) 
ID Identity 
IOFI International Organization of the Flavor Industry 
IP Intraperitoneal 
IR Infrared spectroscopy 
JECFA The Joint FAO/WHO Expert Committee on Food Additives 
LD50 Lethal Dose, 50 %; Median lethal dose 
MS Mass spectrometry 
MSDI
 
Maximised Survey-derived Daily Intake
 
mTAMDI Modified Theoretical Added Maximum Daily Intake 
NMR Nuclear magnetic resonance 
No Number 
NOAEL No Observed Adverse Effect Level 
NOEL No Observed Effect Level 
NTP National Toxicology Program 
OECD Organisation for Economic Co-operation and Development 
SCE sister chromatid exchange 
SCF Scientific Committee on Food 
SMART somatic mutation and recombination test 
TAMDI Theoretical Added Maximum Daily Intake 
TK Thymidine Kinase 
UDS Unscheduled DNA Synthesis 
WHO World Health Organization 
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APPENDICES 
Appendix A.  Summary of safety evaluation 
 Summary of safety evaluation applying the procedure Table 6: 
FL-no EU Register name Structural formula MSDI (a)  
(µg per capita 
per day) 
Class (b) 
Evaluation procedure 
path (c) 
Outcome on the 
named 
compound (d)(e) 
Outcome on the 
material of 
commerce (f)(g)(h) 
Evaluation 
remarks 
02.070 Cyclohexanol 
 
3.7 
 
Class I 
A3: Intake below 
threshold 
d f  
02.075 (1R,2S,5S)-neo-
Dihydrocarveol 
 
2.4 
 
Class I 
A3: Intake below 
threshold 
d f  
02.135 Cyclopentanol 
 
0.012 
 
Class I 
A3: Intake below 
threshold 
d f  
02.167 (1R,2R,5S)-
Isodihydrocarveol 
 
2.4 
 
Class I 
A3: Intake below 
threshold 
d f  
09.154 
1852 
Menthyl valerate 
 
1 
 
Class I 
A3: Intake below 
threshold 
d f  
OH
OH
OH
OH
O
O
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 Summary of safety evaluation applying the procedure Table 6: 
FL-no EU Register name Structural formula MSDI (a)  
(µg per capita 
per day) 
Class (b) 
Evaluation procedure 
path (c) 
Outcome on the 
named 
compound (d)(e) 
Outcome on the 
material of 
commerce (f)(g)(h) 
Evaluation 
remarks 
09.355 neo-Dihydrocarvyl 
acetate 
 
0.012 Class I 
A3: Intake below 
threshold 
d f  
09.618 Menthyl formate 
 
0.73 Class I 
A3: Intake below 
threshold 
d f  
09.619 (1R,2S,5R)-Menthyl 
hexanoate 
 
0.37 Class I 
A3: Intake below 
threshold 
d f  
09.621 (1R,2S,5R)-Menthyl 
salicylate 
 
0.012 Class I 
A3: Intake below 
threshold 
d f  
O
O
OO
O
O
OHO
O
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 Summary of safety evaluation applying the procedure Table 6: 
FL-no EU Register name Structural formula MSDI (a)  
(µg per capita 
per day) 
Class (b) 
Evaluation procedure 
path (c) 
Outcome on the 
named 
compound (d)(e) 
Outcome on the 
material of 
commerce (f)(g)(h) 
Evaluation 
remarks 
09.843 Menthol 1- and 2-
propylene glycol 
carbonate 
 
830 
380 
Class I 
A3: Intake below 
threshold 
d f  
09.870 Carvyl-3-
methylbutyrate 
 
0.0012 
 
Class I 
A3: Intake below 
threshold 
d f Evaluated in 
FGE.212, 
genotoxic 
concern could 
be ruled out 
09.929 L-Monomenthyl 
glutarate 
 
110 Class I 
A3: Intake below 
threshold 
d f  
OH
O
O
O
+
O O
OH
O
O
O
O
O
O
OH
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 Summary of safety evaluation applying the procedure Table 6: 
FL-no EU Register name Structural formula MSDI (a)  
(µg per capita 
per day) 
Class (b) 
Evaluation procedure 
path (c) 
Outcome on the 
named 
compound (d)(e) 
Outcome on the 
material of 
commerce (f)(g)(h) 
Evaluation 
remarks 
09.935 Dimenthyl glutarate 30 Class I 
A3: Intake below 
threshold 
d f  
09.949 L-Menthyl (S)-3-
hydroxybutyrate 
 
37 Class I 
A3: Intake below 
threshold 
d f  
07.059 p-Menthan-3-one 
 
530 
2500 
Class II 
A3: Intake below 
threshold 
d f  
07.109 
1857 
2,6,6-
Trimethylcyclohex-
2-en-1,4-dione 
 
50 
 
Class II 
A3: Intake below 
threshold 
d f Evaluated in 
FGE.213Rev1, 
genotoxicity 
concern could 
be ruled out 
07.202 2,6,6-
Trimethylcyclohex-
2-en-1-one 
 
0.12 
 
Class II 
A3: Intake below 
threshold 
d f Evaluated in 
FGE.212Rev1, 
genotoxic 
concern could 
be ruled out 
O
O
O
O
O
O OH
O
O
O
O
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 Summary of safety evaluation applying the procedure Table 6: 
FL-no EU Register name Structural formula MSDI (a)  
(µg per capita 
per day) 
Class (b) 
Evaluation procedure 
path (c) 
Outcome on the 
named 
compound (d)(e) 
Outcome on the 
material of 
commerce (f)(g)(h) 
Evaluation 
remarks 
07.203 3,3,5-
Trimethylcyclohexan
-1-one 
 
0.0085 
 
Class II 
A3: Intake below 
threshold 
d f  
07.219 trans-3-Methyl-2-(2-
pentenyl)-2-
cyclopenten-1-one 
 
4.7 
 
Class II 
A3: Intake below 
threshold 
d f Evaluated in 
FGE.212Rev3, 
genotoxicity 
concern could 
be ruled out 
07.255 
1856 
l-Piperitone 
 
12 
 
Class II 
A3: Intake below 
threshold 
d f Evaluated in 
FGE.212Rev1, 
genotoxic 
concern could 
be ruled out 
07.207 
 
Cyclotetradecanone 
 
0.061 
 
Class II 
B3: Intake below 
threshold, B4: No 
adequate NOAEL 
Additional data 
required 
 No longer 
supported by 
Flavour 
Industry 
(EFFA, 2009) 
09.520 
1898 
Methyl 3-oxo-2-
pentyl-1-
cyclopentylacetate 
 
770 
 
Class II 
A3: Intake above 
threshold, A4: Not 
endogenous, A5: 
Adequate NOAEL exists 
d f  
O
O
O
R
CH2
CH2
CH2
CH2
CH2
CH2C
H2
H2C
H2C
H2C
H2C
H2C
H2C
O
O
O
O
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 Summary of safety evaluation applying the procedure Table 6: 
FL-no EU Register name Structural formula MSDI (a)  
(µg per capita 
per day) 
Class (b) 
Evaluation procedure 
path (c) 
Outcome on the 
named 
compound (d)(e) 
Outcome on the 
material of 
commerce (f)(g)(h) 
Evaluation 
remarks 
06.136 
1859 
6-Isopropyl-3,9-
dimethyl-1,4-
dioxyspiro[4.5]decan
-2-one 
 
1.2 
 
Class III 
A3: Intake below 
threshold 
d f  
(a): EU MSDI: Amount added to food as flavour in (kg/year) ×  10E9/(0.1 × population in Europe (= 375 × 10E6) × 0.6 × 365) = µg per capita per day. 
(b): Thresholds of concern: Class I = 1 800 µg per person per day, Class II = 540 µg per person per day, Class III = 90 µg per person per day. 
(c): Procedure path A substances can be predicted to be metabolised to innocuous products. Procedure path B substances cannot. 
(d): No safety concern based on intake calculated by the MSDI approach of the named compound. 
(e): Data must be available on the substance or closely related substances to perform a safety evaluation. 
(f): No safety concern at the estimated level of intake of the material of commerce meeting the specification requirement (based on intake calculated by the MSDI approach). 
(g): Tentatively regarded as presenting no safety concern (based on intake calculated by the MSDI approach) pending further information on the purity of the material of commerce and/or 
information on stereoisomerism. 
(h): No conclusion can be drawn because of the lack of information on the purity of the material of commerce. 
 
 
  
O
O
O
Flavouring Group Evaluation 09 Revision 6
 
EFSA Journal 2015;13(9):4243 48 
 Evaluation status of hydrolysis products of candidate esters in FGE.09Rev6 Table 7: 
FL-no EU Register name 
JECFA no 
Structural formula SCF status (a) 
JECFA status (b) 
CoE status (c) 
EFSA status 
Structural class (d) 
Procedure path (JECFA) (e) 
Comments 
Not in 
Register 
Methanol 
 
Not evaluated as flavouring 
substance 
 Not a Register 
substance. 
Not in 
Register 
3-Oxo-2-pentyl-1-
cyclopentyl acetic 
acid 
 
Not evaluated as flavouring 
substance 
 Not a Register 
substance. 
Not in 
Register 
(S)-3-
Hydroxybutyric 
acid 
 
Not evaluated as flavouring 
substance 
 Not a Register 
substance. 
02.015 Menthol 
427 
 
 
No safety concern (JECFA, 
2000a) 
Category A (CoE, 1992) 
 
Class I 
A3: Intake above threshold, 
A4: Not endogenous, A5: 
Adequate NOAEL exists 
NOAEL: 380 mg/kg 
bw/day 
02.062 Carveol 
381 
 
 
No safety concern (JECFA, 
2000a) 
Category B (CoE, 1992) 
 
Class I 
A3: Intake below threshold 
 
02.075 (1R,2S,5S)-neo-
Dihydrocarveol 
 
 
 
 
Category B (CoE, 1992) 
FGE.09 
Class I 
A3: Intake below threshold 
 
H
H
H
OH
O
OH
O
OH
HO
O
OH
OH
OH
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 Evaluation status of hydrolysis products of candidate esters in FGE.09Rev6 Table 7: 
FL-no EU Register name 
JECFA no 
Structural formula SCF status (a) 
JECFA status (b) 
CoE status (c) 
EFSA status 
Structural class (d) 
Procedure path (JECFA) (e) 
Comments 
07.059 p-Menthan-3-one 
 
 
 
 
Category B (CoE, 1992) 
FGE.09 
Class II 
A3: Intake below threshold 
 
08.001 Formic acid 
79 
 
Category 1 (SCF, 1995) 
No safety concern (JECFA, 
1999b) 
Deleted (CoE, 1992) 
 
Class I 
A3: Intake below threshold 
 
08.002 Acetic acid 
81 
 
Category 1 (SCF, 1995) 
No safety concern (JECFA, 
1999b) 
Category A (CoE, 1992) 
 
Class I 
A3: Intake above threshold, 
A4: Endogenous 
 
08.004 Lactic acid 
930 
 
 
No safety concern (JECFA, 
2002a) 
Category A (CoE, 1992) 
 
Class I 
A3: Intake above threshold, 
A4: Endogenous 
 
08.007 Valeric acid 
90 
 
Category 1 (SCF, 1995) 
No safety concern (JECFA, 
1999b) 
Category A (CoE, 1992) 
 
Class I 
A3: Intake below threshold 
 
08.008 3-Methylbutyric 
acid 
259  
Category 1 (SCF, 1995) 
No safety concern (JECFA, 
1999b) 
Category A (CoE, 1992) 
 
Class I 
A3: Intake below threshold 
 
O
OHO
O
OH
OH
OH
O
OH
O
OH
O
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 Evaluation status of hydrolysis products of candidate esters in FGE.09Rev6 Table 7: 
FL-no EU Register name 
JECFA no 
Structural formula SCF status (a) 
JECFA status (b) 
CoE status (c) 
EFSA status 
Structural class (d) 
Procedure path (JECFA) (e) 
Comments 
08.009 Hexanoic acid 
93 
 
Category 1 (SCF, 1995) 
No safety concern (JECFA, 
1999b) 
Category A (CoE, 1992) 
 
Class I 
A3: Intake above threshold, 
A4: Endogenous 
 
08.082 Glutaric acid 
 
 
 
 
 
FGE.10 
Class I 
A3: Intake below threshold 
 
08.112 Salicylic acid 
958 
 
 
No safety concern (JECFA, 
2002a) 
 
 
Class I 
A3: Intake below threshold 
 
(a):  Category 1: Considered safe in use. Category 2: Temporarily considered safe in use. Category 3: Insufficient data to provide assurance of safety in use. Category 4: Not acceptable because 
of evidence of toxicity. 
(b):  No safety concern at estimated levels of intake. 
(c):  Category A: Flavouring substance which may be used in foodstuffs Category B: Flavouring substance which can be used provisionally in foodstuffs. 
(d):  Threshold of concern: Class I = 1 800 µg per person per day, Class II = 540 µg per person per day, Class III = 90 µg per person per day. 
(e):  Procedure path A substances can be predicted to be metabolised to innocuous products. Procedure path B substances cannot. 
O
OH
O
HO
O
OH
O
OH
OH
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SUPPORTING SUBSTANCES SUMMARY 
 Summary of safety evaluation of supporting substances performed by the JECFA Table 8: 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no 
Specification 
available 
MSDI (EU) (a) 
(µg per capita 
per day) 
SCF status (b) 
JECFA status (c) 
CoE status (d) 
Comments 
 2-Isobutyl-4,6-
dimethyldihydro-1,3,5-
dithiazine and 4-isobutyl-
2,6-dimethyldihydro-1,3,5-
dithiazine (mixture) 
S
N
H
S S
N
H
S
(Mixture)
 
3781 
 
101517-87-7 
and 101517-
86-6 
1046 
JECFA 
specification 
(JECFA, 2002c) 
0.1  
No safety concern  
Not in the EU 
Register 
 2-Isopropyl-4,6-dimethyl 
2,6-dimethyldihydro-1,3,5-
dithiazine and 4-isopropyl-
2,6-dimethyldihydro-1,3,5-
dithiazine (mixture) 
S
N
H
S S
N
H
S
(Mixture)
 
3782 
 
104691-41-0 
and 104691-
40-9 
1047 
JECFA 
specification 
(JECFA, 2002c) 
ND  
No safety concern  
Not in the EU 
Register 
02.015 Menthol 
 
 
63 
89-78-1 
427 
JECFA 
specification 
(JECFA, 1998) 
16 000  
No safety concern 
(JECFA, 2000a) 
Category A (CoE, 
1992) 
ADI: 0–4 mg/kg 
bw (JECFA, 
2000a) 
02.061 Dihydrocarveol 
 
2379 
2025 
619-01-2 
378 
JECFA 
specification 
(JECFA, 1998) 
0.37  
No safety concern 
(JECFA, 2000a) 
Category B (CoE, 
1992) 
 
OH
OH
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 Summary of safety evaluation of supporting substances performed by the JECFA Table 8: 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no 
Specification 
available 
MSDI (EU) (a) 
(µg per capita 
per day) 
SCF status (b) 
JECFA status (c) 
CoE status (d) 
Comments 
02.062 Carveol 
 
2247 
2027 
99-48-9 
381 
JECFA 
specification 
(JECFA, 1998) 
9.5  
No safety concern 
(JECFA, 2000a) 
Category B (CoE, 
1992) 
 
02.071 p-Menthan-2-ol 
 
3562 
2228 
499-69-4 
376 
JECFA 
specification 
(JECFA, 2000b) 
0.012  
No safety concern 
(JECFA, 2000a) 
Category B (CoE, 
1992) 
 
02.209 3,3,5-
Trimethylcyclohexan-1-ol 
 
3962 
 
116-02-9 
1099 
JECFA 
specification 
(JECFA, 2002c) 
0.12  
No safety concern 
(JECFA, 2002b) 
 
JECFA name: 
3,3,5-Trimethyl 
cyclohexanol 
02.224 3-(1-Menthoxy)propane-
1,2-diol 
 
3784 
 
87061-04-9 
1408 
JECFA 
specification 
(JECFA, 2005a) 
4.1  
No safety concern 
(JECFA, 2005b) 
 
JECFA name: 
3-L-
Menthoxypropa
ne-1,2-diol 
02.246 p-Menthane-3,8-diol 
 
4053 
 
42822-86-6 
1416 
JECFA 
specification 
(JECFA, 2005a) 
39  
No safety concern 
(JECFA, 2005b) 
 
 
OH
OH
OH
O OH
OH
OH
OH
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 Summary of safety evaluation of supporting substances performed by the JECFA Table 8: 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no 
Specification 
available 
MSDI (EU) (a) 
(µg per capita 
per day) 
SCF status (b) 
JECFA status (c) 
CoE status (d) 
Comments 
07.045 2,2,6-
Trimethylcyclohexanone 
 
3473 
686 
2408-37-9 
1108 
JECFA 
specification 
(JECFA, 2002c) 
2.1  
No safety concern 
(JECFA, 2002b) 
Category B (CoE, 
1992) 
 
07.092 p-Menthan-2-one 
 
3176 
11128 
499-70-7 
375 
JECFA 
specification 
(JECFA, 1998) 
0.012  
No safety concern 
(JECFA, 2000a) 
 
 
07.095 2-(sec-
Butyl)cyclohexanone 
 
3261 
11044 
14765-30-1 
1109 
JECFA 
specification 
(JECFA, 2002c) 
5.1  
No safety concern 
(JECFA, 2002b) 
 
 
07.110 Cycloheptadec-9-en-1-one 
 
3425 
11744 
542-46-1 
1401 
JECFA 
specification 
(JECFA, 2005a) 
0.24  
No safety concern 
(JECFA, 2005b) 
 
 
07.111 3-Methylcyclopentadecan-
1-one 
 
3434 
11135 
541-91-3 
1402 
JECFA 
specification 
(JECFA, 2005a) 
0.37  
No safety concern 
(JECFA, 2005b) 
 
JECFA name: 
3-Methyl-1-
cyclopentadecan
one. 
07.128 Dihydrocarvone 
 
3565 
11703 
7764-50-3 
377 
JECFA 
specification 
(JECFA, 2000b) 
0.012  
No safety concern 
(JECFA, 2000a) 
 
 
O
O
O
O
O
O
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 Summary of safety evaluation of supporting substances performed by the JECFA Table 8: 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no 
Specification 
available 
MSDI (EU) (a) 
(µg per capita 
per day) 
SCF status (b) 
JECFA status (c) 
CoE status (d) 
Comments 
07.148 Cyclohexanone 
 
3909 
11047 
108-94-1 
1100 
JECFA 
specification 
(JECFA, 2002c) 
0.12  
No safety concern 
(JECFA, 2002b) 
 
 
07.149 Cyclopentanone 
 
3910 
11050 
120-92-3 
1101 
JECFA 
specification 
(JECFA, 2002c) 
0.018  
No safety concern 
(JECFA, 2002b) 
 
 
07.176 trans-Menthone 
 
2667 
2035 
89-80-5 
429 
JECFA 
specification 
(JECFA, 1998) 
890  
No safety concern 
(JECFA, 2000a) 
 
JECFA name: 
Menthone. 
CAS No in 
register refers to 
cyclohexanone, 
5-methyl-2-(1-
methylethyl)-, 
(2R,5S)-rel- 
07.180 3-Methylcyclohexanone 
 
3947 
 
591-24-2 
1103 
JECFA 
specification 
(JECFA, 2002c) 
0.12  
No safety concern 
(JECFA, 2002b) 
 
 
O
O
O
(-)menthone shown
O
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 Summary of safety evaluation of supporting substances performed by the JECFA Table 8: 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no 
Specification 
available 
MSDI (EU) (a) 
(µg per capita 
per day) 
SCF status (b) 
JECFA status (c) 
CoE status (d) 
Comments 
09.016 Menthyl acetate 
 
2668 
206 
29066-34-0 
431 
JECFA 
specification 
(JECFA, 1998) 
270  
No safety concern 
(JECFA, 2000a) 
Category B (CoE, 
1992) 
JECFA 
evaluated 
menthyl acetate 
(CAS No 
16409-45-3, 
which does not 
specify isomer). 
CAS No in 
register replaced 
by 89-48-5, 
which refers to 
Cyclohexanol, 
5-methyl-2-(1-
methylethyl)-, 
acetate, 
(1R,2S,5R) 
(SciFinder) 
09.027 Cyclohexyl acetate 
 
2349 
217 
622-45-7 
1093 
JECFA 
specification 
(JECFA, 2002c) 
12  
No safety concern 
(JECFA, 2002b) 
Category B (CoE, 
1992) 
 
09.140 Cyclohexyl propionate 
 
2354 
421 
6222-35-1 
1097 
JECFA 
specification 
(JECFA, 2002c) 
0.012  
No safety concern 
(JECFA, 2002b) 
Category B (CoE, 
1992) 
 
OO
O
O
O
O
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 Summary of safety evaluation of supporting substances performed by the JECFA Table 8: 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no 
Specification 
available 
MSDI (EU) (a) 
(µg per capita 
per day) 
SCF status (b) 
JECFA status (c) 
CoE status (d) 
Comments 
09.143 Carvyl propionate 
 
2251 
424 
97-45-0 
383 
JECFA 
specification 
(JECFA, 2000b) 
0  
No safety concern 
(JECFA, 2000a) 
Category B (CoE, 
1992) 
 
09.160 Cyclohexyl formate 
 
2353 
498 
4351-54-6 
1095 
JECFA 
specification 
(JECFA, 2002c) 
0.012  
No safety concern 
(JECFA, 2002b) 
Category B (CoE, 
1992) 
 
09.215 Carvyl acetate 
 
2250 
2063 
97-42-7 
382 
JECFA 
specification 
(JECFA, 1998) 
4  
No safety concern 
(JECFA, 2000a) 
Category B (CoE, 
1992) 
 
09.216 Dihydrocarvyl acetate 
 
2380 
2064 
20777-49-5 
379 
JECFA 
specification 
(JECFA, 1998) 
9.7  
No safety concern 
(JECFA, 2000a) 
Category B (CoE, 
1992) 
 
09.230 Cyclohexyl butyrate 
 
2351 
2082 
1551-44-6 
1094 
JECFA 
specification 
(JECFA, 2002c) 
0.89  
No safety concern 
(JECFA, 2002b) 
Category B (CoE, 
1992) 
 
O
O
O
O
OO
O
O
O
O
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 Summary of safety evaluation of supporting substances performed by the JECFA Table 8: 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no 
Specification 
available 
MSDI (EU) (a) 
(µg per capita 
per day) 
SCF status (b) 
JECFA status (c) 
CoE status (d) 
Comments 
09.464 Cyclohexyl isovalerate 
 
2355 
459 
7774-44-9 
1096 
JECFA 
specification 
(JECFA, 2002c) 
0.28  
No safety concern 
(JECFA, 2002b) 
Category B (CoE, 
1992) 
 
09.521 Methyl 3-oxo-2-pent-2-
enyl-1-cyclopentylacetate 
 
3410 
10821 
39924-52-2 
1400 
JECFA 
specification 
(JECFA, 2005a) 
26  
No safety concern 
(JECFA, 2005b) 
 
JECFA 
evaluated 
methyl 
jasmonate (CAS 
No 1211-29-6). 
(R)- or (S)- nor 
(E)- or (Z)- not 
specified by 
register CAS No 
ND, No intake data reported.  
(a):  EU MSDI: Amount added to food as flavouring substance in (kg / year) × 10E9 / (0.1 × population in Europe (= 375 × 10E6) × 0.6 × 365) = µg/capita per day.  
(b):  Category 1: Considered safe in use, Category 2: Temporarily considered safe in use, Category 3: Insufficient data to provide assurance of safety in use, Category 4: Not acceptable due to 
evidence of toxicity. 
(c):  No safety concern at estimated levels of intake.  
(d):  Category A: Flavouring substance which may be used in foodstuffs, Category B: Flavouring substance which can be used provisionally in foodstuffs. 
 
O
O
O
O
O
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Appendix B.  Procedure for the safety evaluation 
The approach for a safety evaluation of chemically defined flavouring substances as referred to in 
Commission Regulation (EC) No 1565/2000, named the “Procedure”, is shown in schematic form in 
Figure B.1. The Procedure is based on the Opinion of the SCF expressed on 2 December 1999 (SCF, 
1999), which is derived from the evaluation Procedure developed by JECFA at its 44th, 46th and 49th 
meetings (JECFA, 1995, 1996, 1997, 1999b). 
The Procedure is a stepwise approach that integrates information on intake from current uses, 
structure–activity relationships, metabolism and, when needed, toxicity. One of the key elements in 
the Procedure is the subdivision of flavourings into three structural classes (I, II, III) for which 
thresholds of concern (human exposure thresholds) have been specified. Exposures below these 
thresholds are not considered to present a safety concern. 
Class I contains flavourings that have simple chemical structures and efficient modes of metabolism, 
which would suggest a low order of oral toxicity. Class II contains flavourings that have structural 
features that are less innocuous, but are not suggestive of toxicity. Class III comprises flavourings that 
have structural features that permit no strong initial presumption of safety, or may even suggest 
significant toxicity (Cramer et al., 1978). The thresholds of concern of 1 800, 540 or 90 µg per person 
per day for classes I, II and III, respectively, are derived from a large database containing data on 
subchronic and chronic animal studies (JECFA, 1996). 
In Step 1 of the Procedure, the flavourings are assigned to one of the structural classes. The further 
steps address the following questions: 
• Can the flavourings be predicted to be metabolised to innocuous products12 (Step 2)? 
• Do their exposures exceed the threshold of concern for the structural class (Steps A3 and B3)? 
• Are the flavourings or their metabolites endogenous13 (Step A4)? 
• Does a NOAEL exist on the flavourings or on structurally related substances (Steps A5 and 
B4)? 
In addition to the data provided for the flavouring substances to be evaluated (candidate substances), 
toxicological background information available for compounds structurally related to the candidate 
substances is considered (supporting substances), in order to assure that these data are consistent with 
the results obtained after application of the Procedure. 
The Procedure is not to be applied to flavourings with existing unresolved problems of toxicity. 
Therefore, the right is reserved to use alternative approaches if data on specific flavourings warranted 
such actions. 
 
                                                     
12
 “Innocuous metabolic products”: Products that are known or readily predicted to be harmless to humans at the estimated 
intakes of the flavouring agent” (JECFA, 1997a). 
13
 “Endogenous substances”: Intermediary metabolites normally present in human tissues and fluids, whether free or 
conjugated; hormones and other substances with biochemical or physiological regulatory functions are not included 
(JECFA, 1997a). 
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Decision tree structural class 
Can the substance be predicted to be metabolised to innocuous products? 
Procedure for Safety Evaluation of Chemically Defined Flavouring Substances 
Do the conditions of use result in an intake greater than the  
threshold of concern for the structural class? 
Do the conditions of use result in an intake greater than the  
threshold of concern for the structural class? 
Data must be available on the  
substance or closely related  
substances to perform a safety  
evaluation 
Does a NOAEL exist for the substance which provides an adequate 
margin of safety under conditions of intended use, or does a NOAEL 
exist for s tructurally related substances which is high enough to 
accommodate any perceived difference in toxicity between the 
substance and the related substances? 
 
Does a NOAEL exist for the substance which provides an adequate 
margin of safety under conditions of intended use, or does a NOAEL 
exis t for structurally related substances which is  high enough to 
accommodate any perceived difference in toxicity between the 
substance and the related substances? 
 
  Substance would not be    
expected to be of safety concern 
Is the substance or are its metabolites endogenous? 
Additional data required 
Step 1. 
Step 2. 
Step A3. 
Step A4. 
Step A5. 
Step B3. 
Step B4. 
 Yes  No 
 Yes 
 No 
No 
No 
Yes 
No 
Yes 
Yes 
Yes 
 No 
 
Figure 1:  Procedure for safety evaluation of chemically defined flavouring substances 
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Appendix C.  Use levels/mTAMDI 
C.1 Normal and maximum use levels 
For each of the 18 Food categories (Table 9) in which the candidate substances are used, Flavour 
Industry reports a “normal use level” and a “maximum use level”. According to the Industry the 
“normal use” is defined as the average of reported usages and “maximum use” is defined as the 95th 
percentile of reported usages (EFFA, 2002). The normal and maximum use levels in different food 
categories have been extrapolated from figures derived from 12 model flavouring substances (EFFA, 
2004). 
 Food categories according to Commission Regulation (EC) No 1565/2000 Table 9: 
Food category Description 
01.0 Dairy products, excluding products of category 02.0 
02.0 Fats and oils, and fat emulsions (type water-in-oil) 
03.0 Edible ices, including sherbet and sorbet 
04.1 Processed fruit 
04.2 Processed vegetables (including mushrooms and fungi, roots and tubers, pulses and legumes), 
and nuts and seeds 
05.0 Confectionery 
06.0 Cereals and cereal products, including flours and starches from roots and tubers, pulses and 
legumes, excluding bakery 
07.0 Bakery wares 
08.0 Meat and meat products, including poultry and game 
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms  
10.0 Eggs and egg products 
11.0 Sweeteners, including honey 
12.0 Salts, spices, soups, sauces, salads, protein products, etc. 
13.0 Foodstuffs intended for particular nutritional uses 
14.1 Non-alcoholic (“soft”) beverages, excluding dairy products 
14.2 Alcoholic beverages, including alcohol-free and low-alcoholic counterparts 
15.0 Ready-to-eat savouries 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat)—foods that could not be placed in 
categories 01.0–15.0 
 
The “normal and maximum use levels” are provided by the Flavour industry (Burdock, 1995; EFFA, 
2003a, 2007; Flavour Industry, 2004, 2006a, b, 2007, 2010a, b) for 20 of the 22 candidate substances 
in the present flavouring group (Table 10). 
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 Normal and maximum use levels (mg/kg) for the candidate substances FGE.09Rev5 (Burdock, 1995; EFFA, 2003a, 2007; Flavour Industry, Table 10: 
2004, 2006a, 2006b, 2007, 2010a, 2010b). 
FL-no Food Categories 
Normal use levels (mg/kg) 
Maximum use levels (mg/kg) 
01.0 02.0 03.0 04.1 04.2 05.0 06.0 07.0 08.0 09.0 10.0 11.0 12.0 13.0 14.1 14.2 15.0 16.0 
02.070 3 
15 
2 
10 
3 
15 
2 
10 
– 
– 
4 
20 
2 
10 
5 
25 
1 
5 
1 
5 
– 
– 
– 
– 
2 
10 
3 
15 
2 
10 
4 
20 
5 
25 
2 
10 
02.075 3 
15 
2 
10 
3 
15 
2 
10 
– 
– 
4 
20 
2 
10 
5 
25 
1 
5 
1 
5 
– 
– 
– 
– 
2 
10 
3 
15 
2 
10 
4 
20 
5 
25 
2 
10 
02.135 3 
15 
2 
10 
3 
15 
2 
10 
– 
– 
4 
20 
2 
10 
5 
25 
1 
5 
1 
5 
– 
– 
– 
– 
2 
10 
3 
15 
2 
10 
4 
20 
5 
25 
2 
10 
02.167 3 
15 
2 
10 
3 
15 
2 
10 
– 
– 
4 
20 
2 
10 
5 
25 
1 
5 
1 
5 
– 
– 
– 
– 
2 
10 
3 
15 
2 
10 
4 
20 
5 
25 
2 
10 
06.136 0.0001 
0.0005 
0.0001 
0.0001 
0.0001 
0.0008 
– 
– 
– 
– 
0.001 
0.005 
0.0001 
0.0005 
0.0001 
0.0005 
– 
– 
– 
– 
– 
– 
– 
– 
– 
– 
0.0001 
0.0005 
0.0001 
0.0005 
0.0001 
0.0008 
– 
– 
0.0001 
0.0005 
07.059 – 
– 
– 
– 
15.32 
22.99 
– 
– 
– 
– 
33.27 
52.97 
– 
– 
47.89 
68.1 
– 
– 
– 
– 
– 
– 
– 
– 
– 
– 
– 
– 
4.22 
5.86 
0.87 
2.59 
– 
– 
– 
– 
07.109 7 
35 
2 
10 
3 
15 
2 
10 
– 
– 
4 
20 
– 
– 
5 
25 
1 
5 
1 
5 
– 
– 
– 
– 
2 
10 
3 
15 
2 
10 
4 
20 
5 
25 
2 
10 
07.202 3 
15 
2 
10 
3 
15 
2 
10 
– 
– 
4 
20 
2 
10 
5 
25 
1 
5 
1 
5 
– 
– 
– 
– 
2 
10 
3 
15 
2 
10 
4 
20 
5 
25 
2 
10 
07.203 3 
15 
2 
10 
3 
15 
2 
10 
– 
– 
4 
20 
2 
10 
5 
25 
1 
5 
1 
5 
– 
– 
– 
– 
2 
10 
3 
15 
2 
10 
4 
20 
5 
25 
2 
10 
07.255 0.5 
5 
– 
– 
0.2 
2 
– 
– 
– 
– 
0.5 
5 
– 
– 
1 
10 
– 
– 
– 
– 
– 
– 
– 
– 
0.2 
2 
– 
– 
0.2 
1 
0.2 
2 
5 
50 
0.2 
2 
09.154 7 
35 
5 
25 
10 
50 
7 
35 
– 
– 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
– 
– 
– 
– 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.355 3 
15 
2 
10 
3 
15 
2 
10 
– 
– 
4 
20 
2 
10 
5 
25 
1 
5 
1 
5 
– 
– 
– 
– 
2 
10 
3 
15 
2 
10 
4 
20 
5 
25 
2 
10 
09.520 7 
35 
5 
25 
10 
50 
7 
35 
– 
– 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
– 
– 
– 
– 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.618 7 
35 
5 
25 
10 
50 
7 
35 
– 
– 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
– 
– 
– 
– 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.619 7 
35 
5 
25 
1 
50 
7 
35 
– 
– 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
– 
– 
– 
– 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
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 Normal and maximum use levels (mg/kg) for the candidate substances FGE.09Rev5 (Burdock, 1995; EFFA, 2003a, 2007; Flavour Industry, Table 10: 
2004, 2006a, 2006b, 2007, 2010a, 2010b). 
FL-no Food Categories 
Normal use levels (mg/kg) 
Maximum use levels (mg/kg) 
01.0 02.0 03.0 04.1 04.2 05.0 06.0 07.0 08.0 09.0 10.0 11.0 12.0 13.0 14.1 14.2 15.0 16.0 
09.621 0.5 
2.5 
0.2 
1 
0.5 
2.5 
0.4 
2 
– 
– 
1 
5 
0.2 
1 
2 
10 
0.2 
1 
0.2 
1 
– 
– 
– 
– 
0.3 
1.5 
0.5 
2.5 
0.2 
1 
1 
5 
2 
10 
0.4 
2 
09.843 200 
800 
– 
– 
100 
400 
– 
– 
– 
– 
500 
2 000 
15 
60 
60 
250 
– 
– 
– 
– 
– 
– 
– 
– 
25 
100 
– 
– 
30 
120 
100 
400 
25 
100 
– 
– 
09.870 3 
15 
2 
10 
3 
15 
2 
10 
– 
– 
4 
20 
2 
10 
5 
25 
1 
5 
1 
5 
– 
– 
– 
– 
2 
10 
3 
15 
– 
– 
4 
20 
5 
25 
2 
10 
09.935 1 
15 
1 
15 
10 
150 
1 
15 
1 
15 
100 
1 500 
– 
– 
10 
150 
1 
15 
1 
15 
– 
– 
– 
– 
1 
15 
– 
– 
100 
1 500 
100 
1 500 
1 
15 
1 
15 
09.949 30 
150 
– 
– 
10 
50 
20 
100 
– 
– 
50 
200 
5 
20 
20 
100 
– 
– 
– 
– 
– 
– 
– 
– 
10 
30 
– 
– 
10 
50 
10 
50 
30 
150 
10 
30 
The candidate substances [FL-nos: 07.059, 09.843 and 09.949] are also used in chewing gum, which is not covered by any of the above food categories. The 
normal/maximum use levels for these substances in chewing gum are reported to be 14.34/14.34 mg/kg [FL-no: 07.059], 5 000/20 000 mg/kg [FL-no: 09.843] 
and 500/1 000 mg/kg [FL-no: 09.949]. Under the assumptions that all of the flavouring substances are released from the chewing gum and that the intake 
estimate is 2 g chewing gum per day, the calculation of the mTAMDI of the candidate substance based on the 16 food categories and the use of chewing gum 
sum up to 8 700, 63 000 and 10 600 µg per person per day, respectively. These figures are presented in Tables 5 and 9. 
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C.2 mTAMDI Calculations 
The method for calculation of modified Theoretical Added Maximum Daily Intake (mTAMDI) values 
is based on the approach used by SCF up to 1995 (SCF, 1995). The assumption is that a person may 
consume the amount of flavourable foods and beverages listed in Table 11. These consumption 
estimates are then multiplied by the reported use levels in the different food categories and summed 
up.  
 Estimated amount of flavourable foods, beverages and exceptions assumed to be Table 11: 
consumed per person per day (SCF, 1995) 
Class of product category Intake estimate (g per day) 
Beverages (non-alcoholic) 324.0 
Foods 133.4 
Exception a: Candy, confectionery 27.0 
Exception b: Condiments, seasonings 20.0 
Exception c: Alcoholic beverages 20.0 
Exception d: Soups, savouries 20.0 
Exception e: Others, e.g. chewing gum e.g. 2.0 (chewing gum) 
 
The mTAMDI calculations are based on the normal use levels reported by the Flavour Industry. The 
seven food categories used in the SCF TAMDI approach (SCF, 1995) correspond to the 18 food 
categories as outlined in Commission Regulation (EC) No 1565/2000 and reported by the Flavour 
Industry in the following way (see Table 12): 
• Beverages correspond to food category 14.1. 
• Foods correspond to the food categories 1, 2, 3, 4.1, 4.2, 6, 7, 8, 9, 10, 13 and/or 16. 
• Exception a corresponds to food categories 5 and 11. 
• Exception b corresponds to food category 15. 
• Exception c corresponds to food category 14.2. 
• Exception d corresponds to food category 12. 
• Exception e corresponds to others, e.g. chewing gum. 
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 Distribution of the 16 food categories listed in Commission Regulation (EC) No Table 12: 
1565/2000 into the seven SCF food categories used for TAMDI calculation (SCF, 1995) 
Key 
Food categories according to Commission Regulation 
1565/2000 
Distribution of the seven SCF food 
categories 
Food category Food Beverages Exceptions 
01.0 Dairy products, excluding products of category 02.0 Food   
02.0 Fats and oils, and fat emulsions (type water-in-oil) Food   
03.0 Edible ices, including sherbet and sorbet Food   
04.1 Processed fruit Food   
04.2 Processed vegetables (including mushrooms and fungi, 
roots and tubers, pulses and legumes), and nuts and seeds 
Food   
05.0 Confectionery   Exception a 
06.0 Cereals and cereal products, including flours and starches 
from roots and tubers, pulses and legumes, excluding 
bakery 
Food   
07.0 Bakery wares Food   
08.0 Meat and meat products, including poultry and game Food   
09.0 Fish and fish products, including molluscs, crustaceans 
and echinoderms  
Food   
10.0 Eggs and egg products Food   
11.0 Sweeteners, including honey   Exception a 
12.0 Salts, spices, soups, sauces, salads, protein products, etc.    Exception d 
13.0 Foodstuffs intended for particular nutritional uses Food   
14.1 Non-alcoholic (“soft”) beverages, excluding dairy products  Beverages  
14.2 Alcoholic beverages, including alcohol-free and low-
alcoholic counterparts 
  Exception c 
15.0 Ready-to-eat savouries   Exception b 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat)—
foods that could not be placed in categories 01.0–15.0 
Food   
 
The mTAMDI values (see Table 13) are presented for each of the flavouring substances in the present 
flavouring group, for which the Flavour Industry has provided use and use levels (Burdock, 1995; 
EFFA, 2003a, 2007; Flavour Industry, 2004, 2006a, b, 2007, 2010a, b). The mTAMDI values are only 
given for highest reported normal use levels (see Table 13). 
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 Estimated intakes based on the mTAMDI approach. Table 13: 
FL-no EU Register name mTAMDI  
(µg per person 
per day) 
Structural class Threshold of 
concern (µg per 
person per day) 
02.070 Cyclohexanol 1 600 Class I 1 800 
02.075 (1R,2S,5S)-neo-Dihydrocarveol 1 600 Class I 1 800 
02.135 Cyclopentanol 1 600 Class I 1 800 
02.167 (1R,2R,5S)-Isodihydrocarveol 1 600 Class I 1 800 
09.154 Menthyl valerate 3 900 Class I 1 800 
09.355 neo-Dihydrocarvyl acetate 1 600 Class I 1 800 
09.618 Menthyl formate 3 900 Class I 1 800 
09.619 (1R,2S,5R)-Menthyl hexanoate 3 900 Class I 1 800 
09.621 (1R,2S,5R)-Menthyl salicylate 420 Class I 1 800 
09.843 Menthol 1- and 2-propylene glycol 
carbonate 
63 000 Class I 1 800 
09.870 Carvyl-3-methylbutyrate 1 000 Class I 1 800 
09.929 L-Monomenthyl glutarate  Class I 1 800 
09.935 Dimenthyl glutarate 38 000 Class I 1 800 
09.949 L-Menthyl (S)-3-hydroxybutyrate 10 600 Class I 1 800 
07.059 p-Menthan-3-one 8 700 Class II 540 
07.109 2,6,6-Trimethylcyclohex-2-en-1,4-dione 1 900 Class II 540 
07.202 2,6,6-Trimethylcyclohex-2-en-1-one 1 600 Class II 540 
07.203 3,3,5-Trimethylcyclohexan-1-one 1 600 Class II 540 
07.219 trans-3-Methyl-2-(2-pentenyl)–2-
cyclopenten-1-one 
 Class II 540 
07.255 l-Piperitone 320 Class II 540 
09.520 Methyl 3-oxo-2-pentyl-1-
cyclopentylacetate 
3 900 Class II 540 
06.136 6-Isopropyl-3,9-dimethyl-1,4-
dioxyspiro[4.5]decan-2-one 
0.075 Class III 90 
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Appendix D.  Metabolism 
D.1 Absorption, distribution and elimination 
The candidate substances of secondary alicyclic saturated and unsaturated alcohols, ketones and esters 
of the present flavouring group evaluation are expected to be rapidly absorbed from the 
gastrointestinal tract. Supporting substances evaluated by the JECFA sustain this view (JECFA, 
1999a, 2003). 
D.2 Biotransformation 
The candidate substances are expected to be metabolised through several alternative metabolic 
pathways. Depending on their chemical structure, the possible metabolic reactions are the following: 
D.2.1 Ester hydrolysis 
D.2.2 Reduction of ketone groups and oxidation of alcohol groups 
D.2.3 Oxidation of alkyl groups on alkyl substituted alicyclic ketones and alcohols 
D.2.4 Metabolism to glucuronides 
D.2.5 Metabolism to sulphates 
D.2.1. Ester hydrolysis 
The esters included in this FGE are expected to be hydrolysed enzymatically to carboxylic acids and 
alcohols via carboxylesterases found in most tissues throughout the body, the most important of which 
are the β-esterases (Heymann, 1980). For the one hemiketal ester [FL-no: 06.136] hydrolysis to the 
corresponding cyclic ketone, p-menthan-3-one [FL-no: 07.059] and lactic acid [FL-no: 08.004] is 
expected. 
The supporting substances, menthyl acetate [FL-no: 09.016] and dihydrocarvyl acetate [FL-no: 
09.216] were previously evaluated by JECFA (1999a), but no metabolism studies were available for 
these supporting substances, structurally related to the candidate substances menthyl valerate, neo-
dihydrocarvyl acetate, menthyl formate and menthyl hexanoate [FL-nos: 09.154, 09.355, 09.618 and 
09.619]. The JECFA evaluation was based on a study demonstrating about 75 % and 85 % hydrolysis 
of 1-menthol propylene glycol carbonate and 1-menthol ethylene glycol carbonate, respectively, after 
four hours in liver homogenate. Less than 20 % of these two substances were hydrolysed in gastric 
juice and intestinal fluid (Emberger, 1994a, b). More than 80 % of a radioactively labelled mandelic 
acid of 3,3,5-trimethylcyclohexanol, a cyclohexyl ester structurally related to the candidate substance 
menthyl salicylate [FL-no: 09.621], was hydrolysed after 15 minutes of incubation with rat hepatic 
microsomes (White et al., 1990). 
Based on these data, it is anticipated that candidate esters and the one hemiketal ester [FL-nos: 06.136, 
09.154, 09.355, 09.520, 09.618, 09.619, 09.621, 09.843, 09.870, 09.929, 09.935 and 09.949], after 
intestinal absorption are hydrolysed to the corresponding alcohols/ketone and their corresponding 
carboxylic acids (see Table 7). The simple mono- and di-carboxylic acids [FL-nos: 08.001, 08.002, 
08.004, 08.007, 08.008, 08.009 and 08.082] and 3-hydroxybutyric acid are expected to be completely 
metabolised through common routes of biotransformations. The acids salicylic acid [FL-no: 08.112] 
and 3-oxo-2-pentyl-1-cyclopentyl acetic acid (formed from [FL-no: 09.520]) are anticipated to be 
conjugated and excreted with the urine. 
D.2.2. Reduction of ketone groups and oxidation of alcohol groups 
Seven of the candidate substances [FL-nos: 07.059, 07.109, 07.202, 07.203, 07.219, 07.255 and 
09.520] contain a ketone group, which may be metabolically reduced to a hydroxyl group. This may 
also be expected for the hemiketal ester [FL-no: 06.136] after hydrolysis to ketone. 
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Incubation of human liver microsomes with the supporting substance trans-menthone resulted in 
formation of two metabolites. The major metabolite was a reduction product, (+)-neomenthol and a 
hydroxylation product, 7-hydroxymenthone was a minor metabolite (Miyazawa and Nakanishi, 2006) 
Metabolism of the supporting substance carveol [FL-no: 02.062], the hydrolysis product of carvyl-3-
methylbutyrate [FL-no: 09.870], was studied in vitro. (+)-Carveol and (+)-carvone were incubated 
with liver microsomes from dogs, rabbits, guinea pigs, mice, rats, monkeys and humans. (+)-Carveol 
was oxidised to (+)-carvone by liver microsomes of dogs, rabbits and guinea pigs, but not by those of 
humans, monkeys, rats and mice. On the other hand, the (+)-carvone was reduced to (+)-carveol by 
liver microsomes of all animals examined. These results suggest a species-specific metabolism of (+)-
carveol, and shows that carveol is not converted to carvone in the liver of humans (Shimada et al., 
2002). 
In vivo metabolism of l-menthol was studied in adult male rats by giving the rats 800 mg/kg bw l-
menthol solved in 1 % methyl cellulose solution by gavage every day for 20 days. Control rats were 
given vehicle only. The following metabolites of l-menthol were found in the urine: p-menthane-3,8-
diol, p-menthane-3,9-diol, 3,8-oxy-p-menthane-7-carboxylic acid and 3,8-dihydroxy-p-menthane-7-
carboxylic acid. The main urinary metabolites were p-menthane-3,9-diol and 3,8-dihydroxy-p-
menthane-7-carboxylic acid. Menthone was not detected (Madyastha and Srivatsan, 1988). 
D.2.3. Oxidation of alkyl groups on alkyl substituted alicyclic ketones and alcohols 
Oxidation of alkyl groups have been observed for menthol and for the hydrolysis product of the 
candidate esters neo-dihydrocarvyl acetate [FL-no: 09.355] and menthyl formate [FL-no: 09.618], and 
for the candidate substance 3,3,5-trimethylcyclohexan-1-one [FL-no: 07.203] (Truhaut et al., 1970; 
Yamaguchi et al., 1994). 
D.2.4. Metabolism to glucuronides 
The hydrolysis product menthol, as such or after the oxidation of the alkyl ring substituents, is mainly 
conjugated with glucuronic acid and excreted via the bile in rats. Low levels of oxidation products 
were found in the urine, but no unchanged menthol was detected in the urine, faeces or bile after oral 
administration of radioactive labelled menthol (Yamaguchi et al., 1994). 
The candidate substances isodihydrocarveol and neo-dihydrocarveol [FL-nos: 02.167 and 02.075] are 
also anticipated to be conjugated with glucuronic acid, since dihydrocarveol after application by 
gavage to rabbits was found in the urine as the glucuronide (Hämäläinen, 1912; JECFA, 1999a). 
However, dihydrocarveol was also found to be excreted unchanged (Fischer and Bielig, 1940; JECFA, 
1999a). In rabbits, carvone is reduced to yield carveol, which then is converted to the glucuronic acid 
conjugate and excreted in the urine (Fischer and Bielig, 1940). Carveol, the hydrolysis product of 
carvyl-3-methylbutyrate [FL-no: 09.870] is therefore anticipated to be conjugated with glucuronic acid 
and excreted in the urine. 
Salicylic acid (resulting from hydrolysis of menthyl salicylate [FL-no: 09.621]) is excreted either 
unchanged or as salicyluric acid and salicylic glucuronide (Vree et al., 1994). 
The candidate alicyclic ketones (p-menthan-3-one [FL-no: 07.059], 2,6,6-trimethylcyclohex-2-en-1-
one [FL-no: 07.202], 3,3,5-trimethylcyclohexan-1-one [FL-no: 07.203], trans-3-methyl-2-(2-
pentenyl)-2- cyclopenten-1-one [FL-no: 07.219], l-piperitone [FL-no: 07.255] and methyl 3-oxo-2-
pentyl-1-cyclopentylacetate [FL-no: 09.520]) are anticipated to be reduced to the corresponding 
secondary alcohols. These secondary alcohols and the candidate secondary alcohols cyclohexanol [FL-
no: 02.070], neo-dihydrocarveol [FL-no: 02.075], isodihydrocarveol [FL-no: 02.167] and 
cyclopentanol [FL-no: 02.135] are mainly excreted as conjugates with glucuronic acid. Studies in 
rabbits with the supporting substance cyclohexanone [FL-no: 07.148] and with cyclopentanone and 
cycloheptanone show that 50–70 % of these substances are reduced to the corresponding alcohols (the 
candidate substances cyclohexanol [FL-no: 02.070] and cyclopentanol [FL-no: 02.135] and 
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cycloheptanol), which are conjugated with glucuronic acid and excreted (Elliott et al., 1959; James 
and Waring, 1971). Workers employed in a shoe factory were exposed to small amounts of 
cyclohexane in the air. Cyclohexanol and cyclohexanone were found in the urine of these workers, 
indicating that the same metabolic pathways are also found in humans (Governa et al., 1987). A recent 
study in humans shows that the main metabolite in urine after cyclohexanone or cyclohexanol 
exposure is not cyclohexanol-glucuronide as in rabbit and rats, but 1,2-cyclohexanediol-glucuronide 
(Mráz et al., 1994, 1998). 
When the candidate substance 3,3,5-trimethylcyclohexan-1-one [FL-no: 07.203] was given to rats and 
rabbits glucuronides of 3,5,5-trimethylcyclohexanol were detected in the urine (Truhaut et al., 1979). 
D.2.5. Metabolism to sulphates 
A small fraction of the two candidate substances, cyclopentanol and cyclohexanol [FL-nos: 02.135 
and 02.070], is anticipated to be conjugated with sulphate and excreted in the urine. This is based on 
studies on the structurally related substances cyclopentanone, cyclohexanone and cycloheptanone, 
which were given by gavage to rabbits (1.7–2.3 mmol/kg) and rats (1.8–2.5 mmol/kg), and 1–3 % of 
the dose was found in the urine as sulphate conjugates (James and Waring, 1971). 
D.3 Summary and conclusions 
The 11 esters [FL-nos: 09.154, 09.355, 09.520, 09.618, 09.619, 09.621, 09.843, 09.870, 09.929, 
09.935 and 09.949] included in this FGE are expected to be hydrolysed to the corresponding 
carboxylic acids and alcohols, based on the evaluation of supporting substances (Heymann, 1980; 
Anders, 1989; White et al., 1990; Emberger, 1994a, b). The resulting carboxylic acids are either 
metabolised through common physiological pathways, such as beta-oxidation and the citric acid cycle, 
or excreted in conjugation with glucuronide (Keefer et al., 1987; Vree et al., 1994). 
The one hemiketal ester [FL-no: 06.136] is expected to be hydrolysed to the corresponding cyclic 
ketone, p-menthan-3-one [FL-no: 07.059], and lactic acid [FL-no: 08.004]. 
One of the main pathways for the candidate alcohols and the ketones (after reduction) [FL-nos: 
02.070, 02.075, 02.135, 02.167, 07.059, 07.109, 07.202, 07.203, 07.219 and 07.255] is conjugation 
with glucuronic acid followed by excretion. Menthol, carveol and dihydrocarveol, hydrolysis products 
of [FL-nos: 06.136, 09.154, 09.355, 09.618, 09.619, 09.621, 09.843, 09.870, 09.929 and 09.935], are 
also metabolised via this pathway. Neither menthol nor carveol or dihydrocarveol is anticipated to be 
oxidised to the corresponding ketone. 
Additional pathways involved in the metabolism of the candidate substances are reduction of ketone 
groups, oxidation of alkyl groups of alkyl-substituted alicyclic ketones followed by conjugation with 
glucuronic acid and/or sulphates resulting in excretion. 
Thus, it may be anticipated that these 22 substances will be metabolised to innocuous products. 
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Appendix E.  Toxicity data 
 Acute toxicity Table 14: 
Chemical Name [FL-no] (a) Species  Sex  Route  LD50 
(mg/kg bw)  
Reference  Comments 
Menthol [02.015] Mouse  M  Gavage  2 652  Food and Drug Research 
Laboratories, Inc. (1975)  
 
Mouse  M  Gavage  4 384  Food and Drug Research 
Laboratories, Inc. (1975) 
 
Mouse  NR  Gavage  3 100  Wokes (1932)  
Rat  M, F  Gavage  3 180  Jenner et al. (1964)  
Rat  M  Gavage  940  Food and Drug Research 
Laboratories, Inc. (1975) 
 
trans-Menthone [07.176] Rat  M, F  Oral  1 600–1 950  (Levenstein (1973a), Igimi and 
Ide (1974) 
Test material = racemic 
menthone 
Menthyl acetate [09.016] Rat  M, F  Gavage  > 7 000  Levenstein (1973b) Test material = racemic 
menthyl acetate 
Rat  M, F  Oral  > 5 000  Shelanski (1972) Test material = l-menthyl 
acetate 
Dihydrocarveol [02.061] Rat  NR  Oral  > 5 000  Moreno (1977)  
Dihydrocarvyl acetate [09.216] Rat  NR  Oral  > 5 000  Moreno (1980)  
neo-Dihydrocarvyl acetate [09.355] Rat  NR  Oral  > 5 000  Moreno (1980)  
Cyclopentanol [02.135] Rat  NR  Gavage  < 625  Myers et al. (1980)  
3,5,5-Trimethylcyclohexanol [02.209] Rat  M, F  Oral  3 250  Smyth and Carpenter (1948)  
Cyclohexanone [07.148] Rat  M, F  Oral  1 705  Kohli et al. (1967)  
Rat  M, F  Oral  1 840  Deichmann and LeBlanc (1943)  
Rat  M, F  Oral  1 620  Smyth et al. (1969)  
Rat  M, F  Oral  1 800  Gupta et al. (1979)  
Mouse  M, F  Oral  2 070  Gupta et al. (1979)  
Rabbit  M  Gavage  1 600  Treon et al. (1943)  
Rabbit  M  IP 1 540  Gupta et al. (1979)  
Guinea pig M  IP 930  Price (1951)  
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 Acute toxicity Table 14: 
Chemical Name [FL-no] (a) Species  Sex  Route  LD50 
(mg/kg bw)  
Reference  Comments 
Cyclohexanol [02.070] Rat  M  Gavage  1 750  Miller and Sherman (1965)  
Rat  NR  Oral  1 550  Birch (1978)  
Rat  NR  Oral  2 060 (b) Smyth et al. (1946)  
Rat  NR  Oral  2 060  Bär and Griepentrog (1967)  
Rat  M, F  Oral  1 120  Birch et al. (1981)  
Rabbit  NR  Gavage  2 200–2 600 (c) Treon et al. (1943)  
3-Methylcyclopentadecan-1-one 
[07.111] 
Dog M, F  > 2 000 You et al. (1997)  
Rat M, F  > 5 000 Oh et al. (1997)  
6-Isopropyl-3,9-dimethyl-1,4-
dioxyspiro[4.5]decan-2-one [06.136] 
Rat NR Oral > 2 000 Flavour Industry (2006a)  
Methyl 3-oxo-2-pentyl-1-
cyclopentylacetate [09.520] 
Rat NR Oral > 2 000 Flavour Industry (2006a)  
Carveol [02.062] Rat NR Oral 3 000 Keating (1972)  
Carvyl acetate [09.215] Rat NR Oral > 5 000 Levenstein (1976)  
F, female; M, male; NR, not reported. 
(a): Supporting substances are listed in brackets. 
(b): Administered as 10 % solution in Tergitol 7. 
(c): Minimum lethal dose. 
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 Subacute/subchronic/chronic/carcinogenicity studies Table 15: 
Chemical Name 
[FL-no](a) 
Species; Sex 
No./Group 
Route Dose levels Duration NOAEL 
(mg/kg per day) 
Reference Comments 
(Menthol [02.015]) Mouse; M, F 
2/50 
Diet  2 000, 4 000 ppm 103 
weeks 
600 (b) National Cancer Institute 
(1979) 
Good quality 
Mouse; F 
2/30 
Intraperitoneal 
injection (IP) 
500 and 2 000 mg/kg 
three times week 
24 weeks A NOAEL was not 
determined 
Stoner et al. (1973) Good quality 
Rat; M, F 
3/20 
Gavage  0, 200, 400 and 
800 mg/kg bw day 
28 days < 200 (c) Thorup et al. (1983) Relative good 
quality 
Rat; M, F 
2/80 
Diet  100 and 200 mg/kg 
bw 
5.5 
weeks 
200 (b) Herken (1961) Limited 
information 
Rat; M, F 
2/50  
Diet  3 750 and 7 500 ppm 103 
weeks 
375 (b) National Cancer Institute 
(1979) 
Good quality 
trans-Menthone 
[07.176] 
Rat; M, F 
3/20 
Gavage  200, 400 and 
800 mg/kg bw day 
28 days 400 Madsen et al. (1986) Good quality 
Mouse; F 
2/30 
IP  1 900 and 
4 750 mg/kg 
three times week 
24 weeks A NOAEL was not 
determined (c) 
Stoner et al. (1973) Good quality 
Cyclohexanone 
[07.148] 
Mouse; M, F 
7/20 
Drinking water 400–47 000 ppm 13 weeks M: approx. 3 300, 
F: approx. 6 500 
Lijinsky and Kovatch 
(1986) 
Good quality 
Rat; M, F 
7/10 
Drinking water 190–6 500 ppm 25 weeks Approx. 330 Lijinsky and Kovatch 
(1986) 
Good quality 
Mouse; M, F 
3/84–104 
Drinking water 6 500, 13 000 and (F) 
25 000 ppm 
2 years Approx. 1 600 Lijinsky and Kovatch 
(1986) 
Good quality 
Rat; M, F 
2/104 
Drinking water 3 300 and 6 500 ppm 2 years Approx. 330 Lijinsky and Kovatch 
(1986) 
Good quality 
Rat 
1/7 
IP 200 mg/kg bw (twice 
a day) five 
days/week 
13 weeks A NOAEL was not 
determined (b) 
Perbellini et al. (1981) Only 
neurotoxicity 
was checked. 
Limited 
experimental 
design 
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 Subacute/subchronic/chronic/carcinogenicity studies Table 15: 
Chemical Name 
[FL-no](a) 
Species; Sex 
No./Group 
Route Dose levels Duration NOAEL 
(mg/kg per day) 
Reference Comments 
Cyclohexanol [02.070] Rats 
1/7 
IP 200 mg/kg bw (twice 
a day) five 
days/week 
3 weeks 
(twice a 
day) plus 
3 weeks 
(once a 
day) 
A NOAEL was not 
determined (b) 
Perbellini et al. (1981) Limited 
experimental 
design 
Rat; M 
1/6 
Gavage  455 mg/kg day 7 days 455 (b) Lake et al. (1982) Limited 
quality 
Rat; M 
1/NR 
Drinking water 10 ppm 30 days 1 (b) Messiha and Lox (1985) Limited 
quality 
2-sec-
Butylcyclohexanone 
[07.095] 
Rat 
3/NR 
Diet  91 days 370 Hummler (1969) Study not 
available 
3-
Methylcyclopentadecan-
1-one [07.111] 
Rat, M, F 
3/20 
Gavage  30 days 1 000 (d) Oh et al. (1997)  
Dog, M, F 
3/6 
Gavage  28 days 20 (d) You et al. (1997)  
Methyl 3-oxo-2-pentyl-
1-cyclopentylacetate 
[09.520] 
Rat M, F 
10/10 
Diet 0, 10, 50 or 
100 mg/kg bw day 
90 days 100 Kelly and Bolte (2000)  
IP, intraperitoneal injection; F, female; M, male; NR, not reported  
(a): Supporting substances are listed in brackets. 
(b): The study was performed at a single dose level or multiple dose levels that produced no adverse effects. 
(c): The test substance was administered three times per week for eight weeks; animals were observed for an additional 16 weeks. 
(d): Study was performed with either a single dose or multiple doses that produced no adverse effect. The value is therefore not a true no observed effect level (NOEL), but is the highest dose 
tested that produced no adverse effects. The actual NOEL may be higher. 
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 Developmental and reproductive toxicity studies Table 16: 
Chemical Name 
[FL-no](a) 
Study type 
Duration 
Species/Sex 
No/group 
Route  Dose levels (mg/kg per 
day) 
NOAEL 
(mg/kg per day) 
Including 
information on 
possible maternal 
toxicity 
Reference  
(Menthol [02.015]) Teratology 
Gestation days 6–15 
Mouse; F 
22 
Gavage  0, 1.85, 8.59, 39.9, 185 185 (b) Food and Drug Research 
Laboratories, Inc. (1973) 
Teratology 
Gestation days 6–15 
Rat; F 
22–23 
Gavage  0, 2.18, 10.15, 47.05, 218 218 (b) Food and Drug Research 
Laboratories, Inc. (1973) 
Teratology 
Gestation days 6–15 
Hamster; F 
20–22 
Gavage  0, 4.05, 21.15, 98.2, 405 405 (b) Food and Drug Research 
Laboratories, Inc. (1973) 
Teratology 
Gestation days 6–18 
Rabbit; F 
9–11 
Gavage  0, 4.25, 19.75, 91.7, 425 425 (b) Food and Drug Research 
Laboratories, Inc. (1973) 
Cyclohexanol 
[02.070] 
Reproductive 
NR (c) 
Mouse; M, F 
NR 
Diet  ca. 1 500 (1 %) < 1 500 (< 1 %) Gondry (1972) 
F, female; M, male; NR, not reported. 
(a): Supporting substances are listed in brackets. 
(b): The study was performed at a single dose level or multiple dose levels that produced no adverse effects. 
(c): Animals were exposed during gestation, lactation and weaning over multiple generations. Total length of exposure not reported. 
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 Genotoxicity (in vitro) Table 17: 
Chemical name 
[FL-no] (a) 
Test system Test object  Concentration Result  Reference  Comments 
(Menthol 
[02.015]) 
Ames test  S. typhimurium 
TA92, TA94, TA98, 
TA100, TA1535, 
TA1537 
0, and 6 
concentrations up 
to 5 000 µg/plate 
Negative (b)  Ishidate et al. 
(1984) 
d,l-Menthol was used. The study is considered valid 
Ames test (pre-
incubation 
method) 
S. typhimurium 
TA97, TA98, 
TA100, TA1535 
3–666 µg/plate Negative (b) Zeiger et al. 
(1988) 
d,l-Menthol was used. The study is considered valid 
Ames test  S. typhimurium 
TA98, TA100, 
TA2637 
0, 5–500 µg/plate Negative (b)  Nohmi et al. 
(1985) 
d,l-Menthol was tested. The highest concentrations 
were cytotoxic. The study is considered valid 
Ames test  S. typhimurium 
TA98, TA100, 
TA2637 
0, 20–
500 µg/plate 
Negative (b)  Nohmi et al. 
(1985) 
l-Menthol was tested. The highest concentrations were 
cytotoxic. The study is considered valid 
Ames test  S. typhimurium 
TA98, TA100, 
TA1535, TA1537 
0, 6.4, 32, 160 
and 800 µg/plate 
Negative (b)  Andersen and 
Jensen (1984) 
No indication of which enantiomer was used. In the 
absence of metabolic activation, the highest 
concentration was cytotoxic. The study is considered 
valid 
Ames test  E. coli WP2 uvrA 
(Trp-) 
100–800 µg/plate Negative  Yoo (1986) l-Menthol was used. The article is not in English. The 
validity of the study cannot be evaluated. It is unclear 
whether metabolic activation or a control group was 
used 
Ames test  S. typhimurium 
TA97A, TA98, 
TA100, TA102 
0, 5–800 µg/plate Negative (b)  Gomes-Carneiro 
et al. (1998) 
(-)-Menthol was used. The range of concentrations 
tested varied between the different strains. 
Cytotoxicity was observed with the highest 
concentrations tested with TA97A and, in the presence 
of metabolic activation, the highest concentration 
tested with TA102. The study is considered valid 
Rec assay  B. subtilis H17, M45 Up to 
10 000 µg/disk 
Positive Yoo (1986) l-Menthol was used. Inhibition zone for rec– and rec+ 
was 42 and 23 mm, respectively. The article is not in 
English. It is not clear from the study whether 
metabolic activation or a control group was used. The 
validity of this study cannot be assessed. The method 
(rec-assay) has poor predictive value 
Rec assay  B. subtilis H17, M45 20 µg/disk Negative Oda et al. l-Menthol was used. The article is not in English. 
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 Genotoxicity (in vitro) Table 17: 
Chemical name 
[FL-no] (a) 
Test system Test object  Concentration Result  Reference  Comments 
(1979) Only one concentration level is mentioned in a table. 
No data on metabolic activation or control group. The 
validity of this study cannot be evaluated. The method 
(rec-assay) has poor predictive value 
Alkaline elution 
assay 
Rat hepatocytes  0, 0.1–1.3 mM 
(203.2 µg/ml (c)) 
Negative Storer et al. 
(1996) 
The experiment employed d-Menthol. An increase in 
DNA breaks was observed only at concentrations 
associated with cytotoxicity. The authors concluded 
that this was a false-positive result. The study is 
considered valid 
Sister chromatid 
exchange 
Chinese hamster 
ovary cells 
5–50 and 0, 2–
25 µg/ml (d) 
0, 16–
167 µg/ml (e) 
Negative (b)  Ivett et al. 
(1989) 
d,l-Menthol was used. The compound was tested up to 
toxic or near-toxic concentration levels. The study is 
considered valid 
Sister chromatid 
exchange 
Human lymphocytes 0, 0.1, 1, 10 mM 
(1 563 µg/ml (c)) 
Negative (b)  Murthy et al. 
(1991) 
The study is considered valid 
Cytogenetic 
assay 
Human embryonic 
lung cells 
0, 0.1, 1, 
10 µg/ml 
Negative  Food and Drug 
Research 
Laboratories, 
Inc. (1975) 
The report does not mention exogenous metabolic 
activation. The study is considered valid 
Chromosome 
aberration 
Chinese hamster 
fibroblasts 
0 and three 
concentrations up 
to 200 µg/ml 
Negative (d)  Ishidate et al. 
(1984) 
The maximum concentration (cytotoxic) was selected 
by a preliminary test. The study is considered valid 
Chromosome 
aberration 
Chinese hamster 
ovary cells 
0, 50–250 µg/ml Negative (b)  Ivett et al. 
(1989) 
d,l-Menthol was used. The compound was tested up to 
toxic or near-toxic concentration levels. The study is 
considered valid 
Chromosome 
aberration 
Human lymphocytes 0, 0.1, 1, 10 mM 
(1 563 µg/ml (c)) 
Negative (b)  Murthy et al. 
(1991) 
The study is considered valid 
Gene mutation 
assay 
Mouse lymphoma 
L5178Y TK+/– cells 
0, 12.5–
200 µg/ml 
Negative (b)  Myhr and 
Caspary (1991) 
d,l-Menthol was used. The maximum concentration 
was selected by a preliminary test The study is 
considered valid 
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Chemical name 
[FL-no] (a) 
Test system Test object  Concentration Result  Reference  Comments 
trans-Menthone 
[07.176] 
Ames test  S. typhimurium 
TA97, TA98, 
TA100, TA1535, 
TA1537 
0, 6.4–
800 µg/plate 
Positive (b)  Andersen and 
Jensen (1984) 
Concentrations were selected based on preliminary 
experiments. In the absence of metabolic activation, 
menthone was mutagenic only to strain TA1537 at 6.4 
and 32 µg/ml (slightly less than twofold increase in 
mutation frequency), but not at higher (toxic) 
concentrations. In addition, in the absence of 
metabolic activation, there was a concentration-
dependent increase in number of TA97 strain 
revertants (up to fourfold increase at 600 µg/l). It was 
stated that metabolic activation did not enhance the 
mutagenicity of menthone. The study is considered 
valid 
Cyclopentanol 
[02.135]  
Modified Ames 
test 
S. typhimurium G46, 
TA98, TA100, 
TA1535, C3076, 
TA1537, D3052, 
TA1538 
E. coli WP2, WP2 
uvrA– 
0, 0.1–
1 000 µg/ml 
Negative (b)  McMahon et al. 
(1979) 
The study was performed with agar plates containing 
the following concentration gradients: 0.1–1, 1–10, 
10–100 and 100–1 000 µg/ml. The study is considered 
valid, although tabulated data on cyclopentanol were 
not presented 
(Cyclohexanone 
[07.148]) 
Reverse 
mutation 
S. typhimurium 
TA98, TA100, 
TA1535, TA1537 
33–
3 333 µg/plate 
Negative (b) NTP (2007)  
Ames test  S. typhimurium 
TA98, TA100, 
TA1535, TA1537 
0, 33–
10 000 µg/plate 
Negative (b)  Haworth et al. 
(1983) 
The highest level tested was the highest of either 
10 000 µg/plate, limit of solubility or maximal non-
toxic concentration. The test was run twice. Both rat 
and hamster liver S9 were used. The test is considered 
valid 
Ames test  S. typhimurium 
TA98, TA100, 
TA1535, TA1537 
0, 3 µmol/plate Negative (b)  Florin et al. 
(1980) 
A preliminary assay was performed with the four 
strains using only one concentration level 
(3 µmol/plate). This assay gave uncertain results. In 
addition, strains TA98 and TA100 were exposed to 
0.03–30 µmol/plate. The validity of the study cannot 
be evaluated 
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Chemical name 
[FL-no] (a) 
Test system Test object  Concentration Result  Reference  Comments 
Ames test  S. typhimurium 
TA98, TA100, 
TA1535, TA1537 
NR Positive Massoud et al. 
(1980) 
Only an abstract is available. No reporting with 
respect to metabolic activation. The substance was 
also tested with B. subtilis. With this species, toxicity 
was found, as well as a positive response. The validity 
of the study cannot be evaluated because of the lack of 
experimental information 
Cytogenetic 
assay 
Human leucocytes 0.1–10 mM Inconclusive 
(d)
  
Collin (1971) The study report contains little experimental detail. 
Gaps, but no increase in breaks, were observed 
without any dose–response relationship. There was no 
information with respect to cytotoxicity or presence of 
a control group. Only a statement on observations 
from 12 cells per concentration was given, but the 
total number of cells studied was not specified. The 
study is inadequate 
Chromosomal 
aberration 
Human lymphocytes 0, 0.005–
0.1 µg/ml 
Positive  Dyshlovoi et al. 
(1981) 
Article is not in English. Only an abstract is available 
in English. The validity of the study cannot be 
evaluated 
Gene mutation 
(HPRT) 
Chinese hamster 
ovary cells 
0, 7.5 µg/ml Negative (b)  Aaron et al. 
(1985) 
Only an abstract is available with limited experimental 
information. The validity of the study cannot be 
evaluated 
Chromosomal 
aberration 
Chinese hamster 
ovary cells 
0, 7.5 µg/ml Negative (b)  Aaron et al. 
(1985) 
Only an abstract is available with limited experimental 
information. The validity of the study cannot be 
evaluated 
Sister chromatic 
exchange 
Chinese hamster 
ovary cells 
0, 7.5 µg/ml Positive (d) 
Negative (e) 
Aaron et al. 
(1985) 
Only an abstract is available with limited experimental 
information. The validity of the study cannot be 
evaluated 
Mutation Mouse lymphoma 
L5178Y TK+/– cells 
312.5–
5 000 µg/ml 
Negative NTP (2007)  
Cyclohexanol 
[02.070] 
Ames test  S. typhimurium 
TA98, TA1535, 
TA1537, TA1538 
500–
10 000 µg/plate (d
)
 
500–
15 000 µg/plate (e) 
Negative (b)  Barsky (1976) The highest concentrations showed cytotoxicity. The 
study is considered valid 
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Chemical name 
[FL-no] (a) 
Test system Test object  Concentration Result  Reference  Comments 
Ames test  S. typhimurium 
TA98, TA100, 
TA1535, TA1537 
0, 10–
3 333 µg/plate 
Negative (b)  Haworth et al. 
(1983) 
The highest level tested was the highest of either 
10 000 µg/plate, limit of solubility or maximal non-
toxic concentration. Both rat and hamster liver S9 
were used. The test was run twice. The study is 
considered valid 
Chromosomal 
aberration 
Human leucocytes  0.1–10 mM Inconclusive 
(d)
 
Collin (1971) The study report contains little experimental detail. 
Gaps, but no increase in breaks, were observed 
without any dose–response relationship. There was no 
information with respect to cytotoxicity or presence of 
a control group. Only a statement on observations 
from 12 cells per concentration was given, but the 
total number of cells studied was not specified. The 
study is inadequate 
(Cyclohexyl 
acetate [09.027]) 
DNA damage B. subtilis 
H17(rec+), M45 
(rec–) 
19 mg/disc Negative (b) Yoo (1986)  
(Cyclohexyl 
butyrate 
[09.230]) 
DNA damage B. subtilis 
H17(rec+), M45 
(rec–) 
19 mg/plate Negative (b) Oda et al. 
(1979) 
 
(Cycopentanone 
[07.149]) 
Reverse 
mutation 
S. typhimurium 
TA98, TA100, 
TA1535, TA1537 
2.5–
2 500 mg/plate 
Negative (b) Florin et al. 
(1980) 
 
(2,2,6-Trimethyl 
cyclo-hexanone 
[07.045]) 
Reverse 
mutation 
S. typhimurium 
TA98, TA100, 
TA1535, TA1537 
4.2–
3 600 mg/plate 
Negative (b) Florin et al. 
(1980) 
 
Methyl 3-oxo-2-
pentyl-1-
cyclopentylaceta
te [09.520] 
Reverse 
mutation 
S. typhimurium 
TA98, TA100, 
TA102, TA1535, 
TA1537 
5 mg/plate Negative (b) Thompson 
(2000) 
Valid study in compliance with the OECD Guideline 
471 
Reverse 
mutation 
E. coli WP2 uvrA 5 mg/plate Negative (b) Wagner and 
Klug (2000) 
Valid study in compliance with the OECD Guideline 
471 
Forward 
mutation Test 
Mouse lymphoma 
cells L5178y 
200 or 300 µg/l 
300 µg/l 
Positive (d) 
Positive (e) 
Ross and Harris 
(1979) 
Pre-GLP study—not possible to assess the reliability 
of these studies. 
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Chemical name 
[FL-no] (a) 
Test system Test object  Concentration Result  Reference  Comments 
Forward 
mutation Test 
Mouse lymphoma 
cells L5178y 
100–325 µg/l Negative (b) Cifone (2001) Valid study and in compliance with OECD Guideline 
476 
(Carveol 
[02.062]) 
Ames test (pre-
incubation) 
S. typhimurium 
TA98, TA100, 
TA1535, TA1537 
560 µg/plate Negative (b) Mortelmans et 
al. (1986) 
 
(Carvyl acetate 
[09.215]) 
Ames test (pre-
incubation) 
S. typhimurium 
TA98, TA100, 
TA1535, TA1537 
333 µg/plate Negative (b) Mortelmans et 
al. (1986) 
 
(L-Menthyl 
(R,S)-3-
hydroxybutyrate
) 
Reverse 
mutation 
S. typhimurium 
TA98, TA100, 
TA1535, TA1537 
and TA1538 
78, 156, 312, 
625, 1250, 2 500 
or 
10 000 µg/plate 
Negative (b)(f) Morimoto 
(2005) 
The JECFA evaluated the racemate of L-menthyl 
(R,S)-3-hydroxybutyrate 
Reverse 
mutation 
E. coli WP2 uvrA 78, 156, 312, 
625, 1 250, 2 500 
or 
10 000 µg/plate 
Negative (b)(f) Morimoto 
(2005) 
 
HPRT, hypoxanthine-guanine phosphoribosyltransferase gene; NA, not applicable; NR, not reported. 
(a): Supporting substances are listed in brackets. 
(b): With and without S9 metabolic activation. 
(c): Calculated based on molecular weight of menthol = 156.3 g/mol. 
(d): Without S9 activation. 
(e): With S9 activation. 
(f): Modified pre-incubation method. 
(g): Marked differential toxicity was seen at dose levels above 25 µmol/plate. No observations were noted at lower dose levels. 
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Chemical Name  
[FL-no](a) 
Test System Test Object  Route Dose Result  Reference  Comments 
(Menthol [02.015]) Host mediated 
mutation assay 
S. typhimurium  
TA1530 and 
G46;  
S. cerevisiae D3 
inoculated in 
mice (7-9 
animals/group) 
Gavage  0, 1.45 - 5000 
mg/kg bw 
(single dose) 
0, 1150 mg/kg 
bw per day 
(repeated doses) 
Equivocal Food and Drug 
Research 
Laboratories, 
Inc., 1975 
Negative results, with the 
exception of the combination  
S. typhimurium TA1530 – 5000 
mg/kg bw and S. cerevisiae D3 – 
1150 mg/kg bw per day. This 
study is considered valid, but the 
equivocal result might have low 
relevance since the effect was 
observed at only very high (lethal) 
dose levels. 
In vivo 
cytogenetic assay 
Male rat bone 
marrow cells 
Gavage 0, 1.45 - 3000 
mg/kg bw 
(single dose) 
0, 1150 mg/kg 
bw per day 
(repeated doses) 
Negative Food and Drug 
Research 
Laboratories, 
Inc., 1975) 
Oral DL50 was determined as  
940 mg/kg bw. The study is 
considered valid but the negative 
result is of limited relevance, 
since no effect on mitotic index 
was observed. However, testing at 
higher dose levels may not have 
been possible, because of 
lethality. 
In vivo 
micronucleus 
assay 
B6C3F1 male 
mouse bone 
marrow cells 
Intra 
peritonal 
0, 250 - 1000 
mg/kg bw per 
day, for 3 days 
Negative Shelby et al., 
1993 
d,l-Menthol was used. The study 
is considered valid, but the 
negative result is of limited 
relevance, since no toxicity to the 
bone marrow was observed. 
However, testing at higher dose 
levels was not possible, because 
the highest dose caused 50 % 
lethality. 
In vivo dominant 
lethal assay 
Male rat 
fertility, 
spermatozoa 
Gavage 0, 1.45 - 3000 
mg/kg bw 
(single dose) 
0, 1150 mg/kg 
bw per day 
(repeated doses) 
Negative Food and Drug 
Research 
Laboratories, 
Inc., 1975 
This study is considered valid. 
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Chemical Name  
[FL-no](a) 
Test System Test Object  Route Dose Result  Reference  Comments 
(trans-Menthone 
[07.176]) 
In vivo SMART 
assay 
D. melanogaster 
– flr3 × mwh 
cross  
Whole 
body 
0, 1.3 µl/disk Positive Franzios et al., 
1997 
Somatic Mutation and 
Recombination Test. Only one 
dose level (1.29 µl/disk; slightly 
higher than the LD50) was tested. 
A two-fold increase in mutation 
frequency as compared with 
control was observed. Menthone 
was not recombinogenic. The 
validity of this study is unclear. 
(Cyclohexanone 
[07.148]) 
In vivo sex-linked 
recessive lethal 
mutation 
D. melanogaster  NR 
3 days 
exposure 
0, 1 µl/ml Negative Goncharova, 
1970 
Article in Russian. Only an 
abstract available in English. The 
validity of this study cannot be 
assessed. 
Cyclohexanol 
[02.070] 
In vivo sex-linked 
recessive lethal 
mutation 
D. melanogaster NR 
3 days 
exposure 
0, 1 µl/ml Negative Goncharova, 
1970 
The validity of the study cannot 
be evaluated. 
In vivo 
micronucleus test 
NMRI mouse 
bone marrow  
Oral  500 - 1500 
mg/kg bw 
Negative Gelbke, 1991 The study is considered valid. The 
negative result of this study is of 
limited relevance, since no bone 
marrow toxicity could be 
detected. Testing at higher dose 
levels might not have been 
possible because of observed 
general toxicity at the highest 
dose. 
Methyl 3-oxo-2-
pentyl-1-
cyclopentylacetate 
[09.520] 
Micronucleus test ICR mice Intraperit
onal 
280, 560 or 
1120 mg/kg bw 
Negative Gudi and 
Krsmanovic, 
1998 
Valid study in compliance with 
the OECD Guideline 474. 
Unscheduled 
DNA Synthesis 
Rat hepatocytes Intraperit
onal 
333.3 or 1000 
mg/kg bw 
Negative Durward, 2001 Valid study in compliance with 
the OECD Guideline 486.  
NR: Not reported.  
(a):  Supporting substances are listed in brackets. 
 
